An intracranial teratoma is a germ cell tumor arising within the cranial cavity, composed of tissues derived from two or more embryonic germ layers (ectoderm, mesoderm, and endoderm), most commonly occurring in the pineal or suprasellar regions of children.

Intracranial Teratoma

An intracranial teratoma is a type of germ cell tumour (GCT) arising within the cranial cavity, composed of tissues derived from all three embryonic germ layers — ectoderm, mesoderm, and endoderm. The name itself tells you the pathology:

"Terato-" (Greek: teras = monster) — refers to the bizarre mixture of mature/immature tissues (hair, teeth, skin, cartilage, fat, respiratory epithelium, etc.)
"-oma" = tumour/mass

Intracranial teratomas are a subtype of non-germinomatous germ cell tumours (NGGCTs), and they arise almost exclusively in midline structures of the brain — most commonly the pineal gland and the suprasellar region ^[1]^[2].

Key Concept — Intracranial GCT Classification

Intracranial GCTs are divided into:

Germinoma (60–65% of intracranial GCTs) — marker negative, radiosensitive
Non-germinomatous GCTs (NGGCTs) — includes yolk sac tumour, choriocarcinoma, embryonal carcinoma, teratoma, and mixed GCT

Teratoma is further divided into mature (well-differentiated, benign-behaving) and immature (contains embryonal/fetal tissue elements, more aggressive). A third category, teratoma with malignant transformation, occurs when a somatic component within the teratoma undergoes malignant change (e.g., a sarcoma or carcinoma arising within teratomatous tissue).

2. Epidemiology

Peak incidence: 10–12 years old ^[1]^[2]
Much more common in Asian populations than Caucasians (6:1 ratio) — this is a critical HKU exam fact, directly relevant to Hong Kong ^[1]^[2]
Brain tumours are the 2nd most common childhood malignancy (after haematological malignancies) and the most common solid organ tumour in children ^[3]
Intracranial GCTs account for ~3–5% of paediatric brain tumours in Western populations but ~11–15% in East Asian series (Japan, Taiwan, Korea, Hong Kong) — making them the 3rd most common paediatric brain tumour in HK ^[1]^[3]
Male predominance for pineal gland tumours; female predominance for suprasellar tumours ^[1]^[2]

Teratomas make up ~10–20% of all intracranial GCTs (a minority compared to germinomas)
Congenital intracranial teratomas (presenting at birth or in the neonatal period) are rare but account for the majority of congenital brain tumours — they are often massive, can cause macrocephaly in utero, and carry a very poor prognosis
In infants < 1 year, choroid plexus tumours and teratomas predominate among supratentorial tumours ^[3]
Mature intracranial teratomas have a slight male predominance overall
Immature teratomas and teratomas with malignant transformation are even rarer

Risk Factor	Explanation
Asian ethnicity	6× higher incidence than Caucasians; genetic susceptibility suspected (e.g., HLA associations, unknown germline variants)
Male sex (for pineal location)	Unclear mechanism; possibly hormonal influence on pineal gland development
Klinefelter syndrome (47,XXY)	Associated with extragonadal GCTs including mediastinal and intracranial teratomas; isochromosome 12p [i(12p)] is a characteristic cytogenetic marker of GCTs
Cryptorchidism / gonadal dysgenesis	General risk factor for GCTs (gonadal and extragonadal), suggesting aberrant primordial germ cell migration
Family history of GCTs	Rare familial clustering reported

Why are intracranial GCTs midline? Primordial germ cells (PGCs) migrate during embryogenesis from the yolk sac wall along the midline to the gonadal ridge. If PGCs fail to complete migration and "get stuck" along the midline axis, they can give rise to extragonadal GCTs — in the retroperitoneum, mediastinum, and intracranial midline (pineal, suprasellar). This is the "germ cell migration theory" and explains the universal midline location.

3. Anatomy and Function of Relevant Structures

Understanding why intracranial teratomas present the way they do requires knowing the anatomy of the two main sites: the pineal region and the suprasellar region.

The pineal gland (epiphysis cerebri) sits in the posterior part of the third ventricle, just behind the posterior commissure and above the superior colliculi of the tectum (midbrain)
It produces melatonin (circadian rhythm regulation)
Critical anatomical relationships:
- Cerebral aqueduct of Sylvius: runs immediately ventral to the pineal region → a mass here causes obstructive (non-communicating) hydrocephalus by compressing the aqueduct, blocking CSF flow from the 3rd to the 4th ventricle
- Superior colliculi / pretectal area: sit just below the pineal → compression causes Parinaud syndrome (dorsal midbrain syndrome)
- Internal cerebral veins and vein of Galen: run adjacent → vascular encasement can occur
- Posterior 3rd ventricle: direct tumour growth into the ventricle exacerbates hydrocephalus

The sella turcica houses the pituitary gland; the "suprasellar" region sits above it
Critical anatomical relationships:
- Pituitary stalk (infundibulum): connects hypothalamus to pituitary → compression/infiltration causes diabetes insipidus (DI), hypopituitarism
- Optic chiasm: sits just above the sella → compression causes bitemporal hemianopia (because the crossing nasal fibres from both temporal visual fields are affected first)
- Hypothalamus: involved in temperature regulation, appetite, thirst, hormonal control → infiltration causes endocrine dysfunction, precocious puberty, or hyperphagia
- 3rd ventricle (anteriorly): large suprasellar masses can obstruct the foramen of Monro → hydrocephalus

Basal ganglia / thalamus: can cause contralateral hemiparesis, movement disorders
Cerebral hemisphere: focal deficits depending on location
Cerebellum: ataxia, nystagmus

4. Aetiology and Pathophysiology

During normal embryogenesis:

Primordial germ cells (PGCs) originate in the yolk sac endoderm (~week 3)
PGCs migrate along the dorsal mesentery through the retroperitoneum to reach the gonadal ridge (~weeks 4–6)
Some PGCs travel cranially and are normally eliminated by apoptosis

Pathological mechanism: If PGCs aberrantly survive at ectopic midline locations (e.g., pineal, suprasellar, mediastinum, retroperitoneum), they retain totipotent/pluripotent differentiation capacity and can give rise to GCTs. A teratoma specifically forms when these misplaced germ cells differentiate into tissues from all three germ layers rather than remaining undifferentiated (as in germinoma).

Feature	Detail
Isochromosome 12p [i(12p)]	The hallmark cytogenetic abnormality of GCTs; found in ~80% of malignant intracranial GCTs (less consistently in mature teratomas). Results in gain of 12p material → overexpression of genes like KRAS, CCND2 (cyclin D2) promoting proliferation
KIT/RAS pathway	Activating mutations in KIT and RAS genes found in germinomas; less common in teratomas
Global DNA hypomethylation	Seen in germinomas (resembling PGCs); teratomas show more differentiated methylation patterns
TP53, PTEN	Mutations occasionally identified in immature/malignant teratomas

Subtype	Histological Features	Behaviour
Mature teratoma	Well-differentiated tissues from all three germ layers: skin with adnexal structures (ectoderm), cartilage/bone/muscle (mesoderm), respiratory/GI epithelium (endoderm). No immature elements. Tumour markers negative (AFP −, β-hCG −) ^[1]^[2]	Benign-behaving; may still cause mass effect. Can recur if incompletely resected
Immature teratoma	Contains immature/embryonal tissue elements (esp. neuroepithelium). Graded 0–3 based on proportion of immature tissue. AFP +/−, β-hCG +/− ^[1]^[2]	More aggressive than mature; may respond to chemotherapy
Teratoma with malignant transformation	A differentiated somatic component undergoes malignant change (e.g., rhabdomyosarcoma, squamous cell carcinoma, adenocarcinoma within the teratoma)	Aggressive; often chemo-resistant; surgery is mainstay

Why does it matter to distinguish these? Mature teratomas are marker-negative and chemo/radio-resistant → surgery is the definitive treatment. Immature teratomas may respond to platinum-based chemotherapy. Malignant transformation components require tailored oncological treatment.

This is a critical exam concept. The tumour marker profile helps differentiate GCT subtypes without biopsy (especially important because biopsy of pineal/suprasellar lesions is surgically challenging).

Marker	Source	Elevated in
AFP (alpha-fetoprotein)	Yolk sac differentiation	Yolk sac tumour, immature teratoma (+/−), mixed GCT
β-hCG (beta-human chorionic gonadotropin)	Syncytiotrophoblastic differentiation	Choriocarcinoma, germinoma with syncytiotrophoblastic elements, immature teratoma (+/−), mixed GCT
PLAP (placental alkaline phosphatase)	Non-specific GCT marker	Germinoma, variably in others
c-Kit (CD117)	Stem cell marker	Germinoma (IHC on tissue)

High Yield — Marker Profile of Teratoma

Mature teratoma: AFP NEGATIVE, β-hCG NEGATIVE, PLAP NEGATIVE ^[1]^[2]

Immature teratoma: AFP +/−, β-hCG +/− ^[1]^[2]

This means a pure mature teratoma is marker-negative — just like a pure germinoma. The key differentiator is imaging characteristics (teratomas are heterogeneous with fat/calcification vs. homogeneously enhancing germinomas) and histology.

Tumour markers are more sensitive in CSF than in serum — always measure both ^[3].

5. Classification

Intracranial GCTs
├── Germinoma (60-65%)
│   ├── Pure germinoma
│   └── Germinoma with syncytiotrophoblastic giant cells
└── Non-germinomatous GCTs (NGGCTs) (35-40%)
    ├── Yolk sac tumour (endodermal sinus tumour)
    ├── Choriocarcinoma
    ├── Embryonal carcinoma
    ├── Teratoma
    │   ├── Mature teratoma
    │   ├── Immature teratoma
    │   └── Teratoma with malignant transformation (formerly "teratoma with somatic-type malignancy")
    └── Mixed GCT (contains ≥2 histological components)

Location	Frequency	Predominant Sex	Key Clinical Features
Pineal region	Most common	Male	Obstructive hydrocephalus, Parinaud syndrome
Suprasellar region	2nd most common	Female	DI, visual field defects, endocrine dysfunction
Basal ganglia / thalamus	Rare	—	Hemiparesis, movement disorders
Posterior fossa	Very rare	—	Cerebellar signs, raised ICP
Cerebral hemisphere	Very rare	—	Seizures, focal deficits

Age Group	Teratoma Type	Features
Congenital / Neonatal (< 2 months)	Usually immature or mixed; can be massive	Macrocephaly, bulging fontanelle, respiratory distress; extremely poor prognosis
Infancy / Early childhood (< 1 year)	Mature or immature	Along with choroid plexus tumours, predominate before age 1 ^[3]
Late childhood / Adolescence (10–12 years)	Peak for all intracranial GCTs	Classical pineal/suprasellar presentation

6. Clinical Features

The clinical presentation of intracranial teratoma depends fundamentally on:

Location (pineal vs. suprasellar vs. other)
Size and rate of growth (determines degree of mass effect and raised ICP)
Histological subtype (mature = slow-growing; immature/malignant = faster-growing)
Age of patient (neonates present differently from adolescents)

6.1 Symptoms

Pineal tumours cause obstructive hydrocephalus by compressing the cerebral aqueduct, blocking CSF flow from the 3rd to 4th ventricle ^[1]^[2]^[4].

Symptom	Pathophysiological Basis
Headache — generalised, dull, constant, worse in the morning	↑ICP from CSF accumulation; worse in morning because recumbent position during sleep reduces venous drainage and hypoventilation during sleep → ↑pCO₂ → cerebral vasodilation → ↑ICP ^[4]^[5]
Early morning vomiting — effortless, "projectile", may occur without nausea	Direct stimulation of the area postrema (vomiting centre) in the floor of the 4th ventricle by ↑ICP; "effortless" because it is centrally driven, not from GI irritation ^[5]^[6]
Blurred vision / transient visual obscurations (TVOs)	↑ICP transmitted along the subarachnoid space of the optic nerve sheath → "tourniquet" effect on optic nerve axons → transient ischaemia of optic disc → flickering/greying out of vision lasting seconds ^[7]
Progressive drowsiness / reduced consciousness	↑ICP → bilateral compression of reticular activating system (RAS) in brainstem
Diplopia (binocular)	CN VI (abducens) palsy — a "false localising sign" because CN VI has the longest intracranial course, making it susceptible to stretching/compression from ↑ICP anywhere, not necessarily at the tumour site ^[6]^[7]
Neck stiffness / head tilt	Tonsillar herniation or irritation of posterior fossa meninges

In a child with morning vomiting, unsteady gait, and squint — think raised ICP from posterior fossa/pineal lesion until proven otherwise ^[6]

Symptom	Pathophysiological Basis
Difficulty looking up — vertical gaze palsy	Compression of the pretectal area / superior colliculi → disruption of the vertical gaze centre → Parinaud syndrome ^[1]^[2]
Convergence difficulty	Part of Parinaud syndrome — impaired convergence–retraction nystagmus
"Sunset eyes" in infants	Tonic downward deviation of the eyes due to pressure on the pretectal area; the sclera is visible above the iris — a sign of hydrocephalus in infants

Symptom	Pathophysiological Basis
Polyuria and polydipsia (diabetes insipidus)	Infiltration/compression of the pituitary stalk or posterior pituitary → ↓ADH secretion → inability to concentrate urine → massive dilute urine output → compensatory thirst ^[1]^[2]
Delayed puberty / precocious puberty	Delayed: destruction of gonadotroph function or GnRH neurons in hypothalamus. Precocious: β-hCG-secreting components can stimulate Leydig cells (in boys) mimicking LH → testosterone production → precocious puberty; or hypothalamic hamartoma-like disruption of inhibitory pathways ^[1]^[2]
Growth failure	↓GH secretion from anterior pituitary compression → growth hormone deficiency
Fatigue, cold intolerance, weight gain	Secondary hypothyroidism (↓TSH) from anterior pituitary dysfunction
Visual field loss — "bumping into things on the sides"	Compression of the optic chiasm → bitemporal hemianopia (crossing nasal fibres affected first) ^[1]^[2]
Decreased visual acuity	Direct compression of one or both optic nerves ^[1]^[2]

Symptom	Pathophysiological Basis
Seizures	If the teratoma involves the cerebral cortex or temporal lobe → cortical irritation → epileptiform activity
Hemiparesis / movement disorders	Basal ganglia or thalamic involvement → disruption of motor circuits
Behavioural / cognitive changes	Frontal lobe or hypothalamic involvement; also from chronic hydrocephalus
Macrocephaly (neonatal teratoma)	Massive tumour expansion before skull sutures fuse → increased head circumference; may be detected antenatally on USS

6.2 Signs

Sign	Pathophysiological Basis
Papilloedema (bilateral swollen optic discs with blurred margins, loss of cupping, dilated tortuous veins, peripapillary haemorrhages)	↑ICP → transmitted along subarachnoid space of optic nerve sheath → ↓axoplasmic flow at the optic disc → axonal swelling ^[7]. Important: may not cause obvious vision loss initially, but will have TVOs with postural change ^[6]
Enlarged blind spot on perimetry	Swollen optic disc physically enlarges the blind spot on visual field testing
CN VI palsy — esotropia (inward turning of the eye), inability to abduct the affected eye	False localising sign of raised ICP — CN VI has the longest intracranial course; ↑ICP stretches it over the petrous apex ^[6]^[7]
Bulging anterior fontanelle / splayed sutures / increased head circumference (infants)	In infants, unfused sutures allow the skull to expand with chronic ↑ICP rather than herniate brain
Cushing's triad (late/ominous sign): systemic hypertension + bradycardia + irregular respirations	Brainstem (medullary) compression → ischaemia of vasomotor centre → sympathetic surge → ↑BP → baroreceptor-mediated reflex bradycardia; compression of respiratory centres → Cheyne-Stokes or ataxic breathing ^[4]^[5]
Altered consciousness → coma	Progressive herniation → compression of reticular activating system

Herniation Syndromes — Why They Matter

Intracranial teratomas (especially rapidly growing immature/malignant ones) can cause life-threatening brain herniation:

Uncal herniation (supratentorial mass): ipsilateral fixed dilated pupil (CN III compression against tentorial edge) → contralateral hemiplegia (cerebral peduncle compression) → ↓consciousness
Tonsillar herniation (posterior fossa mass or downward transtentorial herniation): cerebellar tonsils descend through foramen magnum → brainstem compression → Cushing's triad → cardiorespiratory arrest
Upward transtentorial herniation: a pineal/posterior fossa mass can push upward through the tentorial notch

Parinaud syndrome occurs in ~50% of pineal region tumours ^[1]^[2] due to compression of the pretectal area and superior colliculi.

Component	Mechanism
Vertical upward (± downward) gaze palsy	Compression of the vertical gaze centre (rostral interstitial nucleus of the medial longitudinal fasciculus — riMLF — and posterior commissure)
Pseudo-Argyll Robertson pupils (light-near dissociation) — pupils accommodate but do not react to light	Pretectal nuclei receive light reflex afferents from the optic tract; compression disrupts the light reflex pathway while sparing the near/accommodation pathway (which travels more ventrally) ^[1]^[2]
Convergence-retraction nystagmus — on attempted upgaze	Co-contraction of extraocular muscles, especially medial recti, due to aberrant dorsal midbrain input ^[1]^[2]
Lid retraction (Collier sign)	Excessive posterior commissure inhibition of levator palpebrae superioris tone → lid retraction
"Sunset eye" sign (in infants)	Tonic downward eye deviation from supranuclear vertical gaze impairment; sclera visible above the iris

Sign	Detail
Growth retardation (short stature, delayed bone age)	GH deficiency
Delayed sexual development or precocious puberty	Gonadotropin dysfunction or β-hCG-secreting component
Central DI features (low urine osmolality, high serum osmolality, hypernatraemia)	Loss of ADH secretion
Hypothyroid features (dry skin, bradycardia, delayed relaxation of reflexes)	Central (secondary) hypothyroidism
Adrenal insufficiency features (hypotension, hypoglycaemia)	ACTH deficiency — can be life-threatening

Imaging Modality	Teratoma Features
CT brain	Heterogeneous mass with fat (hypodense), calcification (hyperdense), and soft tissue components — this heterogeneity ("birthday cake" appearance) is virtually pathognomonic for teratoma
MRI brain	Mixed signal intensity on T1/T2 reflecting fat (bright T1), calcification (dark on all sequences), soft tissue, and possibly cystic components; variable enhancement

Intracranial GCTs are the 3rd most common paediatric brain tumour in HK (after astrocytoma and PNETs including medulloblastoma) ^[3]
Top 4 paediatric brain tumours in HK: (1) Astrocytoma, (2) PNETs (including medulloblastoma), (3) Germ cell tumours, (4) Ependymoma ^[3]
The 6-fold higher incidence in Asians means that when a Hong Kong child presents with a midline intracranial mass, GCTs (including teratoma) should be high on the differential
HKU teaching emphasises the importance of CSF and serum tumour markers (AFP, β-hCG) in diagnosing intracranial GCTs, since markers are more sensitive in CSF than blood ^[3]

High Yield Summary

Intracranial teratoma = a non-germinomatous GCT (NGGCT) composed of tissues from all three germ layers, arising in midline structures (pineal > suprasellar)
Epidemiology: peak 10–12 years, 6× more common in Asians vs Caucasians, male predominance for pineal, female for suprasellar. 3rd most common paediatric brain tumour in HK
Pathogenesis: aberrant primordial germ cell migration → ectopic totipotent cells in midline → differentiation into multi-lineage tissues
Classification: Mature (marker −, benign-behaving, chemo-resistant) vs Immature (AFP/β-hCG +/−, more aggressive) vs Malignant transformation
Pineal presentation = obstructive hydrocephalus (↑ICP) + Parinaud syndrome (50%) (upgaze palsy, light-near dissociation, convergence-retraction nystagmus)
Suprasellar presentation = endocrine dysfunction (DI, hypopituitarism, precocious/delayed puberty) + visual field defects (bitemporal hemianopia)
Imaging: CT shows pathognomonic heterogeneous mass with fat + calcification + soft tissue
Tumour markers: Mature teratoma = AFP −, β-hCG −; Immature teratoma = AFP +/−, β-hCG +/−; always check both serum AND CSF (CSF is more sensitive)
CN VI palsy is a false localising sign of raised ICP — long intracranial course makes it vulnerable to stretch injury
Cushing's triad (hypertension, bradycardia, respiratory depression) is a late ominous sign of brainstem herniation

Active Recall - Intracranial Teratoma (Definition to Clinical Features)

^[1] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Section on Germ Cell Tumours ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Section on Germ Cell Tumours ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf — Section 11.1.3 Brain Tumors (pp. 429, 432) ^[4] Senior notes: Maksim Medicine Notes.pdf — Section 11.16 Increased ICP (p. 278) ^[5] Lecture slides: GC 111. Raised intracranial pressure and hydrocephalus.pdf ^[6] Lecture slides / Senior notes: AOS - Ophthalmology (Ans:Notes).pdf — Neuro-ophthalmology section ^[7] Senior notes: Ryan Ho Opthalmology.pdf — Papilloedema section (p. 90)

Differential Diagnosis of Intracranial Teratoma

When you encounter a suspected intracranial teratoma, you are really approaching the differential from one of two clinical starting points:

A midline intracranial mass (pineal or suprasellar region) on neuroimaging — what else could it be?
A clinical syndrome — raised ICP with Parinaud syndrome (pineal) or DI with visual field defects (suprasellar) — what pathologies produce these pictures?

The differential diagnosis must therefore be framed around location and clinical presentation, because the approach to a brain tumour is fundamentally "where is the lesion, and what lives there?"

The key principle: histological diagnosis by surgical biopsy is mandatory if serum and CSF tumour markers are normal — to differentiate pure germinoma and mature teratoma from other intracranial tumours such as PNETs, ependymoma, craniopharyngioma, Langerhans cell histiocytosis or metastatic disease ^[1]^[2]. This sentence from the senior notes essentially gives you the exam-relevant differential list.

Why is the DDx so important for intracranial teratoma?

Mature teratoma and pure germinoma are both marker-negative (AFP −, β-hCG −). Without markers to guide you, the differential widens to include any midline intracranial mass. Treatment is radically different: germinoma is exquisitely radiosensitive (excellent prognosis with chemoradiation), mature teratoma is radio/chemo-resistant (surgery is definitive), and craniopharyngioma/LCH/PNET have entirely different management protocols. Getting the diagnosis wrong means giving the wrong treatment.

9.2 Differential Diagnosis by Location

A mass in the pineal region presents with obstructive hydrocephalus (↑ICP) ± Parinaud syndrome ^[1]^[2]^[3].

Differential	Key Distinguishing Features	Why It Mimics Teratoma
Germinoma (most common pineal GCT, ~60-65% of intracranial GCTs) ^[1]^[2]	Homogeneously enhancing on MRI; marker-negative (pure) or β-hCG mildly elevated (syncytiotrophoblastic variant); highly radiosensitive; male predominance; peak 10-12y; c-Kit+, PLAP+ on IHC	Same age, same location, same presenting syndrome; both can be marker-negative → biopsy mandatory to differentiate ^[1]^[2]
Other NGGCTs (yolk sac tumour, choriocarcinoma, embryonal carcinoma, mixed GCT)	Marker-positive: yolk sac → AFP ↑; choriocarcinoma → β-hCG ↑↑; embryonal → variable; mixed → AFP/β-hCG +/−	Same midline location; if markers elevated, diagnosis can be made without biopsy — elevated AFP effectively rules out pure germinoma ^[1]^[2]
Pineal parenchymal tumours (pineocytoma, pineoblastoma)	Pineocytoma: well-circumscribed, slow-growing, adults. Pineoblastoma: aggressive, children (may be part of "trilateral retinoblastoma" — bilateral retinoblastoma + pineoblastoma), marker-negative, may show "exploded" pineal calcification on CT	Pineoblastoma can mimic immature teratoma in age and aggressiveness; trilateral RB should be considered if bilateral retinoblastoma is known ^[4]
Astrocytoma / Glioma (tectal glioma, thalamic glioma) ^[5]^[6]	Tectal gliomas: often low-grade, slow-growing, cause aqueductal stenosis with hydrocephalus; may not enhance; IDH mutation status helps classification. Thalamic gliomas: infiltrative, deeper location	Can present with identical ↑ICP picture; imaging usually shows infiltrative rather than well-circumscribed mass
Meningioma (tentorial / falcotentorial)	Extra-axial, dura-based, homogeneously enhancing, "dural tail" sign; adults > children; isointense on T2W	Rare in children; extra-axial location is the key differentiator
Epidermoid / dermoid cyst	Epidermoid: follows CSF signal but restricts on DWI (pearly appearance). Dermoid: contains fat (bright on T1), may have calcification	Dermoid cyst can mimic teratoma because both contain fat and calcification; however dermoid is a congenital ectodermal inclusion cyst, not a GCT

A suprasellar mass presents with endocrine disturbances (DI, hypopituitarism, precocious/delayed puberty) + ophthalmological abnormalities (bitemporal hemianopia, ↓visual acuity) ^[1]^[2].

Differential	Key Distinguishing Features	Why It Mimics Teratoma
Craniopharyngioma ^[7]	Calcification present in ~50%; cystic + solid; arises from Rathke's pouch remnants; bimodal age: 50% present in childhood, 25% between 20-40y; DI, growth retardation, bitemporal hemianopia, hydrocephalus from 3rd ventricle obstruction — same 4 presentations as suprasellar teratoma	Almost identical clinical and partial imaging overlap; both can have calcification; craniopharyngioma has characteristic "machine-oil" cyst fluid; marker-negative
Pituitary adenoma (PitNET) ^[7]^[8]	Adults > children; well-circumscribed sellar mass that expands upward; functional → hormone hypersecretion (prolactinoma → amenorrhoea/galactorrhoea; GH → acromegaly; ACTH → Cushing's); non-functional → mass effect with bitemporal hemianopia, hypopituitarism	In children, much less common than GCTs; in adults, pituitary adenoma is the most common sellar/suprasellar mass
Suprasellar germinoma	Female predominance for suprasellar location; DI is often the first symptom; marker-negative (pure); homogeneously enhancing	Same endocrine syndrome; differentiated by imaging homogeneity and biopsy
Langerhans cell histiocytosis (LCH) ^[1]^[2]	Can infiltrate pituitary stalk → DI; may have systemic features (skin, bone lesions); thickened pituitary stalk on MRI; marker-negative	Specifically listed in senior notes as a DDx that requires biopsy to differentiate from marker-negative GCTs ^[1]^[2]
Hypothalamic / optic pathway glioma	Often associated with NF1 (neurofibromatosis type 1) ^[9]; low-grade pilocytic astrocytoma; visual loss, precocious/delayed puberty if hypothalamic involvement	Optic pathway glioma is the most common cause of chiasmal compression in children; NF1 association is the key clue
Rathke's cleft cyst	Purely cystic, non-enhancing, between anterior and posterior pituitary; usually incidental but can cause DI and hypopituitarism if large	Simple cystic appearance on MRI differentiates it from heterogeneous teratoma
Arachnoid cyst	CSF-signal cyst, no solid component, no enhancement, no calcification	Simple cyst vs complex heterogeneous mass

For masses in the cerebral hemisphere, basal ganglia, or posterior fossa in children:

Differential	Distinguishing Features
Medulloblastoma (90% of PNETs) ^[5]^[6]	Always in midline cerebellar vermis, peak 5-7y, M > F; ↑ICP from 4th ventricle obstruction + cerebellar signs (truncal ataxia); high propensity for leptomeningeal dissemination
Ependymoma ^[1]^[2]	Derived from ependymal lining of ventricular system; 70% in posterior fossa; mean age 6y; slow-growing; ↑ICP from obstructive hydrocephalus when extending into ventricles; ~10% leptomeningeal spread
Pilocytic astrocytoma ^[5]^[6]	Most common astrocytoma in children, WHO Grade I; classical site is cerebellum; also optic pathway, hypothalamus; low malignant potential; cystic + enhancing mural nodule ("ring + nodule") on MRI
Atypical teratoid/rhabdoid tumour (AT/RT)	Infants and young children (< 3y); highly aggressive; INI1/SMARCB1 loss on IHC; can occur anywhere in CNS; mimics medulloblastoma or PNET on imaging
Brain metastasis ^[3]^[10]	Commonest intracranial tumour in adults (lung, breast, RCC, colon, melanoma); rare in children (neuroblastoma, Wilms tumour, leukaemia can metastasize to CNS); multiple ring-enhancing lesions at grey-white junction with vasogenic oedema
CNS lymphoma ^[3]	Solitary or multifocal; T2W iso/hypointense, prominent diffusion restriction on DWI; classically periventricular/subcortical; associated with immunodeficiency (HIV); very rare in children
Brain abscess ^[5]	Ring-enhancing lesion with restricted diffusion centrally (pus); fever, raised inflammatory markers; history of otitis, sinusitis, congenital heart disease (R→L shunt), immunosuppression

Since many of these differentials present similarly clinically, imaging characteristics are the main way to narrow the differential before biopsy/markers:

Feature	Teratoma	Germinoma	Craniopharyngioma	Pineoblastoma	Pilocytic Astrocytoma
CT density	Heterogeneous: fat (hypodense) + calcification (hyperdense) + soft tissue	Iso/hyperdense, homogeneous	Cystic + calcification (50%)	Hyperdense	Cystic + solid nodule
T1W MRI	Mixed: fat = bright; calcification = dark	Iso/hypointense	Cyst = variable (high protein "machine oil"); solid = isointense	Iso/hypointense	Cyst = dark; nodule = iso
T2W MRI	Mixed signal	Iso/hyperintense	Cyst = hyperintense; solid = variable	Variable	Cyst = bright; nodule = bright
Enhancement	Heterogeneous / variable	Homogeneous, intense	Solid component enhances; cyst wall may enhance	Heterogeneous	Mural nodule enhances intensely
DWI	No significant restriction	May show mild restriction	No restriction	Restricted (hypercellular)	No restriction
Pathognomonic clue	Fat + calcification + soft tissue in a pineal/suprasellar mass	Engulfing pineal calcification	"Machine-oil" cyst fluid, eggshell calcification	"Exploded" pineal calcification	"Ring + nodule" sign

High Yield Exam Point — How to Tell Teratoma from Germinoma on Imaging

Both are midline GCTs in the same age group. The key imaging differentiator:

Teratoma = HETEROGENEOUS mass with fat (hypodense on CT, bright T1), calcification, and soft tissue components
Germinoma = HOMOGENEOUS, intensely enhancing mass

If the mass is heterogeneous with fat and calcification → think teratoma. If homogeneous and brightly enhancing → think germinoma.

Both may be marker-negative (if mature teratoma vs pure germinoma) → biopsy is mandatory ^[1]^[2].

Marker Profile	Most Likely Diagnosis
AFP −, β-hCG −, imaging heterogeneous with fat/calcification	Mature teratoma
AFP −, β-hCG −, imaging homogeneous enhancing	Pure germinoma
AFP −, β-hCG mildly ↑	Germinoma with syncytiotrophoblastic elements
AFP ↑↑, β-hCG −	Yolk sac tumour (or immature teratoma)
AFP −, β-hCG ↑↑	Choriocarcinoma
AFP +/−, β-hCG +/−	Mixed GCT, immature teratoma
All markers −, non-GCT imaging features	Craniopharyngioma, pineocytoma, glioma, LCH — biopsy mandatory ^[1]^[2]

Elevated AFP can be assumed to contain elements of yolk sac tumours or immature teratomas and can effectively rule out pure germinoma ^[1]^[2]

Since many intracranial teratomas present with raised ICP, it is useful to consider the broader DDx of ↑ICP ^[5]^[11]:

Aetiology of raised ICP ^[5]:

SOL: tumour, abscess, haematoma
Cerebral oedema: trauma, infection, post-stroke
Hydrocephalus: obstructive (IVH, tumour), communicating (post-meningitis, post-SAH)
Idiopathic intracranial hypertension (IIH)

Features suggestive of SOL ^[11]:

Visual field defects
CN abnormalities: anisocoria / diplopia / new-onset squint
CN6 palsy: "false localising sign"
Papilloedema / "sunset" eye sign in infants: suggest ↑↑ICP
Abnormal gait
Torticollis (tilting of head)
Growth failure, precocious/delayed puberty (e.g. hypothalamic lesion)

Congenital intracranial teratomas are a special situation — they present at birth or antenatally with massive macrocephaly. The DDx includes:

Differential	Distinguishing Features
Congenital intracranial teratoma	Often massive, heterogeneous with fat/calcification; very poor prognosis
Choroid plexus papilloma / carcinoma	Intraventricular, hypervascular, homogeneously enhancing; causes hydrocephalus by CSF overproduction; commoner in lateral ventricles in infants
Congenital glioblastoma	Extremely rare; solid enhancing hemispheric mass
AT/RT	Age < 3y; loss of INI1 on IHC; aggressive
Desmoplastic infantile ganglioglioma	Large cystic + solid; superficial hemispheric location; good prognosis despite size

High Yield Summary — Differential Diagnosis of Intracranial Teratoma

The core DDx for a marker-negative midline intracranial mass in a child: pure germinoma, mature teratoma, craniopharyngioma, pineocytoma, glioma, ependymoma, LCH — biopsy is mandatory
If markers are positive (AFP or β-hCG), the differential narrows to NGGCTs (yolk sac tumour, choriocarcinoma, immature teratoma, mixed GCT) — biopsy may not be needed
Imaging is the key discriminator: teratoma = heterogeneous with fat + calcification; germinoma = homogeneous, intensely enhancing; craniopharyngioma = cystic with eggshell calcification
In HK, intracranial GCTs are 6× more common than in Caucasians → always high on the DDx for midline paediatric brain mass
Pineal region DDx: germinoma > teratoma > pineoblastoma > glioma
Suprasellar region DDx: craniopharyngioma > germinoma > teratoma > optic pathway glioma > pituitary adenoma > LCH > Rathke's cleft cyst

Active Recall - DDx of Intracranial Teratoma

References

^[1] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Section on Germ Cell Tumours (p. 531-532) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Section on Germ Cell Tumours (p. 1259-1260) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf — Section 11.1.3 Brain Tumors (pp. 429-432) ^[4] Senior notes: Ryan Ho Opthalmology.pdf — Retinoblastoma section (p. 119; trilateral RB) ^[5] Senior notes: Maksim Medicine Notes.pdf — Section 11.16 Increased ICP (p. 278) ^[6] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Features of Different Brain Tumours (p. 530) ^[7] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf — Craniopharyngioma section ^[8] Senior notes: Ryan Ho Endocrine.pdf — Pituitary adenoma / Acromegaly (p. 111) ^[9] Senior notes: Adrian Lui Pediatrics Notes.pdf — NF1 section (p. 148) ^[10] Senior notes: Ryan Ho Neurology.pdf — Brain Metastasis (p. 164) ^[11] Senior notes: Maksim Paediatric Notes.pdf — Space-occupying lesions (p. 120)

Diagnostic Criteria, Diagnostic Algorithm, and Investigations for Intracranial Teratoma

Unlike many medical conditions, there is no single "diagnostic criteria checklist" for intracranial teratoma. Instead, diagnosis relies on an integrated approach combining three pillars:

Clinical presentation (symptoms and signs pointing to a midline intracranial mass)
Tumour markers (serum AND CSF AFP and β-hCG — to classify GCT subtype)
Histopathological confirmation (the gold standard — required for marker-negative masses)

The reason for this three-pillar approach is straightforward: treatment differs radically between GCT subtypes and non-GCT tumours. Germinomas are exquisitely radiosensitive (chemoradiation alone can be curative), whereas mature teratomas are radio- and chemo-resistant (surgery is the only definitive treatment). Getting it wrong means either over-treating or under-treating.

High Yield — When Can You Diagnose Without Biopsy vs When Must You Biopsy?

NGGCTs may be diagnosed based on tumour markers elevation ^[1]^[2]:

Elevated AFP can be assumed to contain elements of yolk sac tumours or immature teratomas and can effectively rule out pure germinoma ^[1]^[2]
If β-hCG is markedly elevated → choriocarcinoma or mixed GCT

Histological diagnosis by surgical biopsy is mandatory if serum and CSF tumour markers are normal ^[1]^[2]:

This situation arises with pure germinoma (marker-negative) and mature teratoma (marker-negative)
Must differentiate from PNETs, ependymoma, craniopharyngioma, Langerhans cell histiocytosis, or metastatic disease ^[1]^[2]

Subtype	Diagnostic Basis	Marker Profile	Histological Requirement
Mature teratoma	Marker-negative → biopsy mandatory	AFP −, β-hCG −	Yes — shows well-differentiated tissues from all 3 germ layers (skin, cartilage, respiratory epithelium, etc.) without immature elements
Immature teratoma	May be diagnosed by markers if AFP elevated; otherwise biopsy	AFP +/−, β-hCG +/−	Recommended — shows immature/embryonal tissue, especially immature neuroepithelium; grading based on proportion of immature tissue
Teratoma with malignant transformation	Usually requires biopsy	Variable — depends on somatic malignant component	Mandatory — must identify the specific malignant somatic component (e.g., rhabdomyosarcoma, adenocarcinoma arising within teratoma)
Mixed GCT containing teratoma	Often diagnosed by markers (AFP and/or β-hCG elevated from the non-teratomatous components)	AFP +/−, β-hCG +/−	Recommended for complete histological characterisation

The clinical approach follows a logical sequence: presentation → imaging → markers → ± biopsy → integrated diagnosis.

10.4 Investigation Modalities — Detailed Breakdown

A. Neuroimaging

Why CT first? CT is the first-line emergency imaging modality for any child presenting with symptoms of raised ICP ^[3]^[5]^[12]. It is fast (~1 minute), widely available, and excellent at detecting:

Acute hydrocephalus (dilated ventricles proximal to obstruction)
Calcification (hyperdense)
Fat (hypodense)
Acute haemorrhage (hyperdense)
Mass effect and midline shift

CT brain findings in intracranial teratoma ^[3]^[12]:

Feature	Appearance	Pathological Basis
Heterogeneous mass	Mix of hypodense, isodense, and hyperdense areas	Different tissue types: fat = hypodense, soft tissue = isodense, calcification/bone/teeth = hyperdense
Fat component	Hypodense areas (negative HU, similar to subcutaneous fat)	Mature ectodermal differentiation producing sebaceous material and adipose tissue
Calcification	Hyperdense foci, may be chunky, amorphous, or tooth-like	Mesodermal differentiation into bone, cartilage, or teeth
Obstructive hydrocephalus	Dilated lateral and 3rd ventricles with normal 4th ventricle (if pineal); or dilated lateral ventricles (if suprasellar obstructing foramen of Monro)	Mass compressing cerebral aqueduct or foramen of Monro
Variable enhancement	Heterogeneous or minimal	Reflects variable vascularity and BBB disruption across different tissue components

Normal brain tissue does not enhance on contrast CT due to intact BBB. Enhancement indicates tissue outside the BBB (e.g., meningioma) or disruption of BBB (e.g., high-grade tumours, inflammation) ^[3]^[12]

High Yield — Imaging Interpretation Principle

When evaluating any intracranial mass on CT, systematically note ^[12]:

Location / distribution
Number (multiplicity → metastasis or disseminated infection)
Imaging characteristics: size, shape, outline, attenuation
Contrast enhancement: degree and pattern
Effect on adjacent structures (mass effect, herniation)

For intracranial teratoma specifically: the presence of fat AND calcification within a single midline mass is virtually pathognomonic — no other common tumour shows this combination in the pineal/suprasellar region.

MRI with contrast is generally preferred over CT for intracranial tumours ^[3] because it allows better soft tissue delineation and is especially useful at skull base, craniocervical junction, and brainstem ^[3].

MRI findings in intracranial teratoma:

Sequence	Teratoma Appearance	Why
T1-weighted	Mixed signal: hyperintense areas (fat, proteinaceous material) + hypointense areas (soft tissue)	Fat is bright on T1 due to short T1 relaxation time; solid tissue components are darker
T2-weighted	Mixed signal: hyperintense (cystic/fluid areas) + hypointense (calcification, fibrous tissue)	Water/cyst fluid has long T2 (bright); calcification and dense fibrous tissue are dark on T2
FLAIR	Variable; cystic components may not be fully suppressed (proteinaceous content)	FLAIR suppresses pure CSF but not proteinaceous fluid
Fat-suppressed sequences	Bright T1 areas become dark if they represent fat	Confirms that the T1-bright component is indeed fat (not haemorrhage or proteinaceous fluid, which do NOT suppress)
DWI	No significant diffusion restriction (unlike lymphoma or pineoblastoma)	Teratomas are not highly cellular; no restricted water movement
Post-gadolinium T1	Heterogeneous enhancement of solid components; cystic and fatty areas do not enhance	Only vascularised soft tissue components with disrupted BBB enhance

Comparison with other midline tumours on MRI ^[3]:

Tumour	MRI Appearance
High-grade glioma	↓T1W, heterogeneous enhancement with surrounding vasogenic oedema (↑T2W) ± central necrosis ^[3]
Low-grade glioma	↑T2W, non-enhancing expansile lesion WITHOUT surrounding vasogenic oedema ^[3]
Primary CNS lymphoma	Solitary/multifocal T2W-iso/hypointense, contrast-enhancing lesions in subcortical regions, classically with prominent diffusion restriction on DWI ^[3]
Brain metastasis	Round, well-circumscribed contrast-enhancing lesion with variable signal on T1/T2W ± surrounding oedema, multiple regions especially if multiple intracranial compartments ^[3]
Meningioma	Extra-axial, dura-based T1W-hypo/isointense, T2W-iso/hyperintense lesion with strong homogeneous enhancement ^[3]

Functional imaging is used for pre-operative planning ^[3]:

Functional MRI (fMRI): identify important cortical areas to guide surgical resection ^[3] — maps eloquent cortex (motor, speech, visual) by measuring BOLD signal during task performance
MRI diffusion tensor imaging (DTI / tractography): identify important white matter tracts to guide surgical resection ^[3] — shows the course of corticospinal tracts, optic radiations, etc. relative to the tumour

MR spectroscopy (MRS):

Helps differentiate tumour from non-neoplastic lesions
Teratomas may show a lipid peak (reflecting fat content) and variable choline:NAA ratio

SPECT scan ^[1]^[2]:

Single photon emission CT (SPECT) utilizes various isotopes such as thallium-201 to detect abnormalities in BBB
Functions: distinguish benign from malignant brain lesions; predict histological grade of brain tumours; select areas for biopsy ^[1]^[2]

Required to assess for leptomeningeal dissemination ("drop metastases")
Especially important for immature teratoma and mixed GCTs, which have higher propensity for CSF spread
Should be performed before surgery (to avoid post-operative enhancement artefact) when possible
Look for enhancing nodules on the spinal cord surface or cauda equina

This is one of the most critical investigations in the work-up of any suspected intracranial GCT.

Why tumour markers are so important:

They can subtype the GCT without biopsy (when elevated)
They guide treatment intensity (germinoma = less intensive; NGGCT = more aggressive)
They provide a monitoring tool for treatment response and recurrence

Measurement of tumour markers in serum and CSF: both samples should be obtained unless contraindicated ^[1]^[2]

Measurement of AFP and β-hCG is more sensitive in CSF than in serum ^[1]^[2]^[3]

Marker	Normal Range	Significance if Elevated	Caveats
AFP (alpha-fetoprotein)	< 10 ng/mL in adults; physiologically elevated in neonates/infants (can be > 100,000 ng/mL at birth, normalises by ~8 months)	Elevated AFP = yolk sac tumour elements or immature teratoma ^[1]^[2]; effectively rules out pure germinoma	Must interpret in context of age for infants; hepatic disease can also elevate AFP
β-hCG	< 5 mIU/mL	Markedly ↑ → choriocarcinoma; mildly ↑ → germinoma with syncytiotrophoblastic elements	β-hCG < 50 mIU/mL in CSF may be seen in germinoma with syncytiotrophoblasts
PLAP (placental alkaline phosphatase)	Low/absent in serum	Positive in germinomas (serum/IHC); variable in others	Not routinely measured in serum; mainly used on tissue IHC
LDH	Normal range varies by lab	Non-specific tumour marker; elevated in many malignancies including GCTs	Useful for monitoring treatment response but not for diagnosis

Marker interpretation for teratoma specifically:

Teratoma Subtype	AFP	β-hCG
Mature teratoma	Negative	Negative
Immature teratoma	+/− (may be mildly elevated if contains yolk sac elements)	+/−
Teratoma with malignant transformation	Variable	Variable
Mixed GCT containing teratoma	+/− (depends on other components)	+/−

Exam Pearl — Why Measure Markers in BOTH Serum and CSF?

The blood-brain barrier (BBB) means that small amounts of tumour-secreted AFP/β-hCG may not reach the systemic circulation in sufficient concentration to be detected in serum. However, these markers diffuse freely into the CSF surrounding the tumour. Therefore, CSF markers are more sensitive than serum markers ^[1]^[2]^[3]. A CSF:serum ratio of AFP or β-hCG > 1 strongly suggests intracranial GCT origin rather than a systemic source.

LP serves dual purposes in suspected intracranial teratoma:

Tumour markers (AFP, β-hCG in CSF — as above)
CSF cytology — to detect malignant cells indicating leptomeningeal dissemination

Important caveats:

LP is contraindicated if there is raised ICP with risk of herniation — suspect if immunocompromised, seizure, GCS < 15, focal neurological deficit → CT brain first ^[5]^[13]
If obstructive hydrocephalus is present (very common with pineal teratomas), LP carries a risk of transtentorial or tonsillar herniation → the mass must be addressed first (e.g., external ventricular drainage or tumour resection) before LP is safe
CSF may be obtained intraoperatively during ventricular drainage

CSF findings in intracranial teratoma:

Opening pressure: elevated if ↑ICP/hydrocephalus
Cell count: may show malignant cells (immature teratoma, mixed GCT); mature teratoma usually has normal cytology unless cyst rupture has occurred
Protein: may be mildly elevated
Glucose: usually normal (unlike infection)

D. Histopathological Diagnosis — The Gold Standard

Histological examination of biopsy specimen remains the most important component of diagnostic evaluation of brain tumours ^[1]^[2]

Histological confirmation is obtained at the time of surgical exploration for resection ^[1]^[2]

Method	When Used	Advantages	Disadvantages
Stereotactic biopsy	When mass is deep-seated, in eloquent cortex, or when gross total resection is not feasible	Minimally invasive; guided by CT/MRI coordinates	Small sample → sampling error (mixed GCTs may be missed); risk of haemorrhage along biopsy tract
Endoscopic biopsy	Pineal region tumours — can be combined with endoscopic third ventriculostomy (ETV) for hydrocephalus	Simultaneous diagnostic and therapeutic procedure; direct visualisation	Limited sample size
Open surgical biopsy / resection	When gross total resection is planned (especially for mature teratoma)	Large tissue sample → reduced sampling error; therapeutic if complete resection achieved	More invasive; higher surgical morbidity

Subtype	Key Histological Features
Mature teratoma	Well-differentiated tissues from all 3 germ layers: keratinising squamous epithelium with hair follicles and sebaceous glands (ectoderm), cartilage, bone, smooth muscle (mesoderm), respiratory or GI-type epithelium (endoderm). No mitotic activity. No immature elements
Immature teratoma	Immature tissue elements, most commonly immature neuroepithelium (primitive neuroectodermal rosettes). Graded 0–3 based on proportion of immature tissue per low-power field
Teratoma with malignant transformation	A recognisable somatic malignancy arising within an otherwise teratomatous background (e.g., rhabdomyosarcoma, adenocarcinoma, squamous cell carcinoma)

Marker	Staining Pattern	Utility
PLAP	Positive in germinoma; variable in teratoma	Helps distinguish germinoma from teratoma
c-Kit (CD117)	Positive in germinoma; negative in mature teratoma	Germinoma marker
OCT4	Positive in germinoma and embryonal carcinoma; negative in mature teratoma	Pluripotency marker — helps confirm undifferentiated GCT components
AFP (tissue)	Positive in yolk sac elements	Identifies yolk sac components in immature/mixed teratoma
β-hCG (tissue)	Positive in syncytiotrophoblastic elements	Identifies choriocarcinomatous components
Glypican-3	Positive in yolk sac tumour	Additional yolk sac marker
INI1/SMARCB1	Retained in teratoma; lost in AT/RT	Crucial to exclude atypical teratoid/rhabdoid tumour (AT/RT) — a very aggressive mimicker in young children

Critical Pitfall — Do Not Confuse Intracranial Teratoma with AT/RT

Atypical teratoid/rhabdoid tumour (AT/RT) can mimic teratoma histologically in young children (the name even contains "teratoid"). AT/RT is defined by loss of INI1 (SMARCB1) on IHC. This distinction is critical because AT/RT is extremely aggressive and requires intensive multimodal therapy, whereas mature teratoma is benign-behaving and treated with surgery alone.

For suprasellar teratomas, a complete anterior and posterior pituitary hormone profile is essential ^[14]:

Test	What It Assesses	Expected Abnormality
Serum and urine osmolality + serum Na⁺	Central diabetes insipidus (CDI)	Serum osmolality ↑ ( > 295 mOsm/kg), urine osmolality ↓ ( < 300 mOsm/kg), hypernatraemia
Water deprivation test → DDAVP	Confirms CDI and differentiates from nephrogenic DI	In CDI: urine fails to concentrate during water deprivation; urine osmolality rises after DDAVP administration ^[14]
Free T4, TSH	Secondary (central) hypothyroidism	Low fT4 with low/inappropriately normal TSH
Morning cortisol, ACTH ± short Synacthen test	Secondary adrenal insufficiency	Low morning cortisol ( < 100 nmol/L diagnostic; > 500 nmol/L excludes), inadequate Synacthen response
GH, IGF-1 ± GH stimulation test	GH deficiency	Low IGF-1 for age; inadequate GH rise on stimulation
LH, FSH, oestradiol/testosterone	Hypogonadotropic hypogonadism or precocious puberty	Low LH/FSH with low sex steroids (delayed puberty); or elevated sex steroids with low-normal LH/FSH (β-hCG-driven precocious puberty in boys)
Prolactin	Stalk effect	Mildly elevated ( < 3× upper limit) due to loss of dopaminergic inhibition from pituitary stalk compression ^[14]

For all endocrine investigations, after realising the posterior pituitary is abnormal, you must also check the anterior pituitary hormones — holistic plan to not miss anything ^[14]

Investigation	Findings	Clinical Significance
Visual acuity	Decreased if optic nerve/chiasm compressed	Documents baseline for monitoring
Visual field testing (perimetry)	Bitemporal hemianopia (suprasellar); enlarged blind spot (papilloedema)	Chiasmal compression; raised ICP
Fundoscopy	Swollen optic disc with blurred margins, loss of disc cupping, tortuous veins, peripapillary haemorrhage → papilloedema ^[6]; No obvious vision loss initially, but will have transient BOV for head postural change ^[6]	Raised ICP
Ocular motility	CN VI palsy (esotropia, impaired abduction); vertical gaze palsy (Parinaud)	False localising sign of ↑ICP; dorsal midbrain compression

For suspected raised ICP in a child: neuroimaging (usually posterior fossa / pineal lesion) → MRI brain with contrast to look for intracranial tumour ^[6]

Test	Purpose
CBC with differential	Baseline haematology; pre-chemotherapy assessment
Renal function, electrolytes	Baseline; hypernatraemia in DI; pre-chemotherapy renal function
Liver function tests	Baseline; AFP can also be elevated in liver disease (must exclude)
Clotting profile	Pre-operative assessment; pre-LP safety (INR > 1.5 or Plt < 50 = contraindication) ^[5]
G6PD status	Pre-chemotherapy screen (some drugs cause haemolysis in G6PD deficiency)
Viral serology	Hepatitis B/C, HIV — baseline before chemotherapy and blood products

Once diagnosis is confirmed, staging determines the extent of disease and guides treatment:

Investigation	Purpose
MRI brain with gadolinium	Already done; defines tumour extent, invasion, relationship to critical structures
MRI whole spine with gadolinium	Detect leptomeningeal ("drop") metastases — enhancing nodules on cord/cauda equina
CSF cytology (if safe to perform LP)	Detect malignant cells in CSF — indicates leptomeningeal dissemination
Serum + CSF AFP and β-hCG	Baseline for monitoring; classify GCT subtype; post-treatment normalisation confirms response

Note: TNM staging is NOT useful for primary intracranial tumours ^[3]^[8] because extracranial metastasis is rare (no lymphatic drainage from the brain). Instead, staging is based on the extent of intracranial/spinal disease and the marker profile.

Category	Investigations	Key Findings for Teratoma
Neuroimaging	CT brain → MRI brain with gadolinium → MRI spine	Heterogeneous midline mass with fat + calcification; hydrocephalus; ± spinal drop metastases
Tumour markers	Serum + CSF AFP and β-hCG	Mature: both negative; immature: AFP +/−, β-hCG +/−
Histopathology	Stereotactic biopsy / endoscopic biopsy / surgical resection	Tissues from all 3 germ layers; immature neuroepithelium if immature subtype
IHC	PLAP, c-Kit, OCT4, AFP, β-hCG, INI1	Mature teratoma: all markers negative; INI1 retained (vs lost in AT/RT)
Endocrine	Pituitary hormone profile, water deprivation test	Central DI, hypopituitarism if suprasellar location
Ophthalmology	VA, VF, fundoscopy, ocular motility	Papilloedema, bitemporal hemianopia, CN VI palsy, Parinaud syndrome
Baseline bloods	CBC, LRFT, clotting, G6PD, viral serology	Pre-treatment baseline
CSF	Cytology, markers	Leptomeningeal dissemination if malignant cells present

High Yield Summary — Diagnosis of Intracranial Teratoma

Three-pillar approach: Clinical presentation → tumour markers (serum + CSF) → histopathology
If markers elevated (AFP and/or β-hCG): can diagnose NGGCT subtype without biopsy; elevated AFP rules out pure germinoma ^[1]^[2]
If markers negative: biopsy is mandatory — must differentiate mature teratoma from pure germinoma, craniopharyngioma, PNET, ependymoma, LCH ^[1]^[2]
CT findings: heterogeneous midline mass with fat (hypodense) + calcification (hyperdense) — virtually pathognomonic
MRI findings: mixed T1/T2 signal; fat confirmed by fat-suppression sequences; heterogeneous enhancement
Histopathology is the gold standard — "histological examination of biopsy specimen remains the most important component of diagnostic evaluation of brain tumours" ^[1]^[2]
CSF markers are more sensitive than serum markers — always measure both ^[1]^[2]^[3]
INI1 IHC is critical to exclude AT/RT in young children — retained in teratoma, lost in AT/RT
For suprasellar teratomas: complete endocrine work-up including both anterior and posterior pituitary hormones ^[14]
Staging: MRI spine + CSF cytology — TNM staging is not useful for intracranial tumours

Active Recall - Diagnosis and Investigations for Intracranial Teratoma

References

^[1] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Section on GCT diagnosis (p. 531-532) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Section on GCT diagnosis (p. 1260-1262) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf — Section 11.1.3 Brain Tumors (pp. 429-432) ^[5] Senior notes: Maksim Medicine Notes.pdf — Lumbar puncture indications/contraindications (p. 237), Increased ICP (p. 278-279) ^[6] AOS material: AOS - Ophthalmology (Ans:Notes).pdf — Neuro-ophthalmology case ^[8] Senior notes: Ryan Ho Neurology.pdf — Intracranial Tumours, general principles (p. 161) ^[12] Senior notes: Ryan Ho Diagnostic Radiology.pdf — CT interpretation principles (pp. 39-40, 50) ^[13] Senior notes: Maksim Medicine Notes.pdf — Lumbar puncture contraindications (p. 237) ^[14] Senior notes: Block A - Two cases of polyuria and polydipsia.pdf — Endocrine investigation approach (p. 2)

Management Algorithm and Treatment Modalities for Intracranial Teratoma

The management of intracranial teratoma is fundamentally different from other intracranial GCTs because of a crucial biological fact: mature teratoma is composed of fully differentiated somatic tissues (skin, cartilage, fat, bone) that are neither radiosensitive nor chemosensitive. You cannot shrink a tooth or a piece of cartilage with cisplatin or gamma rays. This single principle drives the entire treatment algorithm.

Contrast this with:

Germinoma: exquisitely radiosensitive (resembles seminoma of testis) → chemoradiation is curative
Other NGGCTs (yolk sac tumour, choriocarcinoma, embryonal carcinoma): moderately chemosensitive → platinum-based chemotherapy + radiation
Mature teratoma: chemo/radio-resistant → surgery is the definitive and often only effective treatment
Immature teratoma: partially chemosensitive (the immature elements may respond) → surgery + adjuvant chemotherapy ± radiation
Teratoma with malignant transformation: the somatic malignant component dictates treatment (often chemo-resistant; surgery is mainstay)

Core Management Principle

Germinoma has more favourable prognosis and requires less intensive treatment. NGGCTs have poorer prognosis and require more aggressive treatment — longer duration of chemotherapy since less chemo-sensitive, and wider field of irradiation including both brain and spinal cord irradiation (craniospinal irradiation/CSI) ^[1]^[2]

For teratoma specifically: surgery first, always. The question is what to add afterwards.

The management of intracranial teratoma proceeds in a systematic order:

Emergency management of raised ICP / hydrocephalus (if present)
Definitive surgery — maximal safe resection
Adjuvant therapy — guided by histological subtype and staging
Endocrine replacement — for suprasellar tumours with pituitary dysfunction
Surveillance and rehabilitation

11.3 Emergency Management of Raised ICP

Many intracranial teratomas — particularly pineal region tumours — present with acute obstructive hydrocephalus requiring emergency intervention before definitive tumour surgery can be planned.

Measure	Mechanism	Details
Head elevation 30°	Facilitates venous drainage from the head via gravity → reduces intracranial venous blood volume → ↓ICP	Simple, immediate, no equipment needed
High-dose glucocorticoids	Reduction of cerebral oedema — specifically vasogenic oedema (fluid leaking from capillaries through disrupted BBB into white matter around the tumour) ^[8]	PO or IV dexamethasone 10 mg loading then 4 mg Q4h or 8 mg BD ^[8]. Why dexamethasone? It is the most potent glucocorticoid with minimal mineralocorticoid activity, and it stabilises the BBB by restoring tight junction integrity
Osmotic therapy	Mannitol or hypertonic saline draw water out of brain parenchyma by osmotic gradient → ↓brain volume → ↓ICP	Used for acute deterioration or impending herniation; temporary bridge to surgery
Anticonvulsants	Treatment or secondary prophylaxis of seizures, usually levetiracetam (Keppra) ^[8]	NOT for infratentorial lesions; usually NOT for primary prophylaxis ^[8]. Why levetiracetam? Broad-spectrum, minimal drug interactions, does not induce hepatic enzymes

High Yield — Steroid Contraindication

Steroids are contraindicated if CNS lymphoma is suspected → steroids cause acute lysis of lymphocytes → decreased diagnostic yield on biopsy ^[8]

This is important because primary CNS lymphoma can mimic any intracranial mass. If there is any diagnostic uncertainty, obtain biopsy BEFORE starting steroids. However, if the imaging is clearly consistent with teratoma (fat + calcification), steroids can be started.

Procedure	Mechanism	When Used
External ventricular drain (EVD)	Manometric principle for monitoring intracranial CSF pressure; therapeutic by draining CSF for decompression ^[15]^[16]	Acute hydrocephalus with impending herniation; allows simultaneous ICP monitoring and CSF drainage; also allows CSF sampling for tumour markers and cytology
Endoscopic third ventriculostomy (ETV)	Creates an opening in the floor of the 3rd ventricle → CSF bypasses the obstructed aqueduct and drains directly into the interpeduncular cistern	Preferred for obstructive hydrocephalus from pineal tumours; can be combined with endoscopic biopsy of the tumour in the same procedure
VP shunt (ventriculoperitoneal)	Diverts CSF from lateral ventricle to peritoneal cavity via a subcutaneous catheter	Rarely first-line for tumour-related hydrocephalus; risk of peritoneal seeding with malignant GCTs; used if ETV fails or for permanent CSF diversion

EVD is the gold standard for ICP monitoring ^[15]^[16]. It serves dual purposes: diagnostic (measure ICP, sample CSF) and therapeutic (drain CSF to lower ICP).

ICP monitoring indications ^[15]^[16]:

No reliable clinical monitoring (e.g., sedation, muscle paralysis)
GCS ≤ 8 (requires intubation)
Evolving disease conditions

Relative contraindications ^[15]^[16]:

Awake patients
Coagulopathy / bleeding tendency

EVD risks: infection, iatrogenic trauma ^[15]

LP contraindicated if raised ICP (with exception...) ^[15] — the "exception" refers to therapeutic LP in IIH, not in obstructive hydrocephalus where LP carries a significant herniation risk.

11.4 Definitive Surgery — Maximal Safe Resection

Maximal safe resection without causing serious neurological sequelae is the key component of treatment ^[1]^[2]

Resection confirms diagnosis, relieves increased ICP, and establishes local control ^[1]^[2]

This statement, though written about medulloblastoma in the senior notes, applies equally — or even more so — to intracranial teratoma, where gross total resection (GTR) is the single most important prognostic factor for mature teratoma. If you can get it all out, the patient is cured.

Approach	When Used	Rationale
Craniotomy — flap of bone cut and reflected ^[8]	Standard approach for most pineal and suprasellar teratomas	Provides wide exposure for en-bloc or piecemeal resection of heterogeneous teratoma tissue
Occipital transtentorial approach	Pineal region tumours	Approaches the pineal region from above the tentorium through the occipital lobe; good for large pineal masses
Infratentorial supracerebellar approach	Pineal region tumours	Approaches from below the tentorium, retracting the cerebellum inferiorly; gravity-assisted in the sitting position; preserves occipital cortex
Transcallosal / interhemispheric approach	Tumours extending into the 3rd ventricle	Accesses the ventricle by splitting the corpus callosum
Transsphenoidal approach (transnasal endoscopic or sub-labial) ^[17]	Suprasellar teratomas	Route of choice for pituitary/suprasellar lesions ^[17]; extended transsphenoidal approach can reach suprasellar tumours
Transcranial (transfrontal) approach ^[17]	For those with very large suprasellar extension, severe chiasmal compression ^[17]	Used when transsphenoidal access is insufficient
Burr hole ^[8]	Often for biopsy ^[8]	Used for stereotactic biopsy when resection is not feasible
Endoscopic approach	Small pineal tumours; combined with ETV	Minimally invasive; limited by tumour size

Image-guided surgery ^[8]:

Frameless stereotaxy: small skull markers allowing intraoperative localisation of handheld probe in relation to skull, tumour (localised in pre-op imaging) ± important structures (by fMRI or tractography) → guidance of resection ^[8]

Functional monitoring ^[8]:

Evoked potentials: detection of cortical electrical response to sensory stimuli or peripheral motor response to cortical electrical stimuli ^[8] — crucial when operating near motor cortex, visual pathways, or brainstem
Awake craniotomy: intraoperative electrical stimulation of cortex → observe speech response to map speech cortex → guide resection to avoid affecting speech ^[8] — not typically used for pineal/suprasellar surgery but relevant for hemispheric teratomas

5-ALA-guided resection ^[8]:

5-aminolevulinic acid (5-ALA) accumulated in tumour cells → intraoperative UV light application → tumour shows different colour ^[8] — primarily used for high-grade gliomas; limited utility in teratoma (differentiated tissues do not reliably take up 5-ALA)

Frozen section ^[18]:

Indications of frozen section — guides intraoperative surgical decisions (confirm or exclude malignancy, margin status) ^[18]
In teratoma surgery, intraoperative frozen section confirms the histological nature of the mass and alerts the surgeon if unexpected malignant components are present

Subtype	Surgical Goal	Rationale
Mature teratoma	Gross total resection (GTR) — aim for complete removal	GTR is curative; no effective adjuvant therapy exists for mature tissue. If GTR is achieved, no further treatment is needed
Immature teratoma	Maximal safe resection → followed by adjuvant chemotherapy ± radiation	Debulking reduces tumour burden; immature elements may partially respond to chemotherapy
Teratoma with malignant transformation	Maximal safe resection → followed by adjuvant therapy tailored to the malignant component	The somatic malignancy may be chemo-resistant; complete resection is critical for survival
Mixed GCT containing teratoma	Maximal safe resection (especially of residual teratoma after chemotherapy) → "second-look surgery"	After initial chemotherapy for the chemo-sensitive components, residual mass often represents mature teratoma ("growing teratoma syndrome") requiring surgical excision

Post-operative complications of brain tumour surgery ^[1]^[2]^[8]:

Complication	Mechanism	Details
Haemorrhage	Intraoperative or postoperative bleeding from tumour bed or bridging veins	May require re-exploration; more common in vascular tumours
CSF leak / rhinorrhoea (transsphenoidal)	Disruption of dural/arachnoid barrier → CSF flows through the surgical defect into the nose	Will require antibiotics to prevent ascending meningitis, as well as decision to go back to OT for repair ^[17]
Meningitis	Ascending infection through CSF leak or postoperative wound infection	Prophylactic antibiotics peri-operatively; monitor for fever, meningism
Iatrogenic hypopituitarism / diabetes insipidus ^[17]	Surgical damage to pituitary stalk, hypothalamus, or posterior pituitary (especially in suprasellar surgery)	Requires long-term hormone replacement (DDAVP for DI, hydrocortisone, thyroxine, sex steroids, GH)
Posterior fossa syndrome (cerebellar mutism) ^[1]^[2]	Postoperative complication caused by injury to cerebellar vermis or dentate nuclei during resection of midline posterior fossa tumours. Appears 1–2 days after surgery and resolves within weeks to months. Characterised by impaired language production with emotional lability ^[1]^[2]	More commonly described after medulloblastoma surgery, but can occur after any posterior fossa surgery including pineal approach
Visual deterioration	Damage to optic pathways during suprasellar or pineal surgery	Pre-operative mapping with DTI/fMRI essential
Seizures	Cortical irritation from surgical manipulation	Postoperative anticonvulsant prophylaxis if cortex involved
Residual/recurrence ^[17]	Especially for large tumours	Regular surveillance MRI; may require re-operation

11.5 Adjuvant Therapy

Indication	Regimen	Rationale
Immature teratoma	Platinum-based: cisplatin + etoposide ± ifosfamide/cyclophosphamide (similar to testicular NSGCT protocols)	Immature neuroepithelial elements are moderately chemosensitive; chemotherapy targets the rapidly dividing immature cells
Teratoma with malignant transformation	Tailored to the somatic malignant component; often platinum-based	Efficacy variable; depends on the specific somatic malignancy
Mixed GCT containing teratoma	Standard NGGCT protocol: cisplatin + etoposide + ifosfamide/cyclophosphamide (e.g., SIOP CNS GCT II protocol)	Treats the chemo-sensitive non-teratomatous components (yolk sac, choriocarcinoma, embryonal carcinoma)
Mature teratoma (pure)	No chemotherapy indicated	Fully differentiated tissues are not dividing → chemotherapy (which targets dividing cells) is ineffective

Chemotherapy in paediatric brain tumours is used as an adjunct to surgery and radiotherapy ^[1]^[2]:

Decreases incidence of recurrence
Minimizes craniospinal radiation exposure
Delays or avoids irradiation to the developing brain and spinal cord
Treats high-risk disease that is not amenable to surgical resection

Chemotherapy complications ^[1]^[2]:

Ototoxicity (cisplatin-induced) — sensorineural hearing loss; monitor with serial audiometry
Nephrotoxicity (cisplatin) — monitor renal function; adequate hydration essential
Myelosuppression — neutropenic fever risk; monitor CBC
Nausea/vomiting — anti-emetic prophylaxis (ondansetron, dexamethasone)
Peripheral neuropathy (cisplatin, vincristine)
Fertility — gonadal toxicity from alkylating agents; consider sperm/oocyte cryopreservation before treatment

Indication	Field and Dose	Rationale
Pure mature teratoma	No radiotherapy indicated	Differentiated tissues are radioresistant
Immature teratoma	Focal radiation to tumour bed ± involved field	Post-chemotherapy consolidation; reduces local recurrence
Teratoma with malignant transformation	Focal ± extended field depending on the malignant component	Variable radiosensitivity depending on somatic malignancy type
Mixed GCT with teratoma component	Wider field of irradiation required including both brain and spinal cord irradiation (craniospinal irradiation/CSI) ^[1]^[2]	Treats microscopic leptomeningeal dissemination from chemo-sensitive components

Craniospinal radiation is avoided or delayed in children due to severe toxicity to the rapidly developing CNS such as neurocognitive impairment ^[1]^[2]

Radiotherapy complications ^[1]^[2]:

Ototoxicity
Short stature (↓GH)
Endocrine abnormalities: ↓GH (94%), ACTH deficiency (43%), TSH deficiency (10%)
Cerebrovascular abnormalities (stroke, intracranial haemorrhage)
Neurocognitive impairment — particularly devastating in young children (< 3 years); this is why chemotherapy-only strategies are preferred in very young children to delay or avoid radiation
Radiation necrosis — can mimic recurrence on imaging
Secondary malignancy — long-term risk (meningioma, glioma)

Why Avoid CSI in Young Children?

The developing brain is exquisitely vulnerable to radiation injury. Myelination continues until age 5–7, and neuronal pruning/synaptic organisation continues through adolescence. CSI in young children causes severe neurocognitive impairment (↓IQ by 20–30 points), growth failure (both from direct spinal irradiation and from GH deficiency), and endocrine dysfunction. This is why chemotherapy-only or chemotherapy-first strategies exist for children < 3 years with intracranial GCTs — to delay radiation until the brain is more mature.

A unique phenomenon in mixed GCTs containing teratoma is the "growing teratoma syndrome":

After chemotherapy, the chemo-sensitive malignant components (yolk sac, choriocarcinoma) regress
However, the chemo-resistant mature teratoma component continues to grow or even enlarge
On imaging: the residual mass enlarges despite normalisation of tumour markers
This is NOT treatment failure — it represents selection and growth of the benign teratomatous elements
Management: "second-look surgery" to resect the residual mature teratoma

This concept parallels the management of residual retroperitoneal mass after chemotherapy for testicular NSGCT, where ~40% of residual masses contain mature teratoma requiring surgical excision ^[19].

For suprasellar teratomas causing hypopituitarism, lifelong hormone replacement is usually required:

Deficiency	Replacement	Monitoring
Central DI	DDAVP (desmopressin) — intranasal or oral	Serum Na⁺, urine osmolality, fluid balance
ACTH deficiency (most dangerous)	Hydrocortisone — physiological replacement (10-15 mg/m²/day in divided doses); stress dosing during illness	Morning cortisol; clinical assessment; must be replaced BEFORE thyroxine (replacing thyroxine before cortisol can precipitate adrenal crisis by increasing cortisol clearance)
TSH deficiency	Levothyroxine	Free T4 (TSH is unreliable in central hypothyroidism)
Gonadotropin deficiency	Sex steroids at pubertal age (oestrogen/progesterone in girls, testosterone in boys); fertility treatment later	Tanner staging, bone age, sex steroid levels
GH deficiency	Recombinant GH — typically started after tumour surveillance period to ensure no recurrence	IGF-1 levels, growth velocity; caution: GH may theoretically promote tumour recurrence (controversial)

Modality	Frequency	Purpose
MRI brain ± spine with gadolinium	Every 3–6 months for first 2 years, then 6–12 monthly for 5 years, then annually	Detect recurrence or progression
Serum + CSF AFP and β-hCG	With each MRI (serum); CSF if clinically indicated	Rising markers suggest recurrence (especially immature teratoma or mixed GCT components)
Endocrine assessment	6–12 monthly	Monitor for evolving pituitary dysfunction (can worsen after surgery or radiation)
Neurocognitive testing	Baseline and periodic	Detect radiation- or surgery-related cognitive decline
Audiometry	Baseline and periodic if cisplatin used	Monitor for ototoxicity
Ophthalmology	6–12 monthly	Visual fields and acuity — especially for suprasellar lesions

11.8 Special Scenarios

Often massive at birth with macrocephaly; frequently diagnosed antenatally on USS
Usually immature or mixed with malignant components
Prognosis is very poor due to:
- Enormous tumour size limiting surgical resectability
- Young age limiting radiation and chemotherapy options
- Frequent involvement of critical structures
Management: surgical debulking if feasible → chemotherapy (radiation avoided in neonates)

Recurrence of mature teratoma is typically local (from residual tumour after subtotal resection)
Management: re-operation for maximal safe re-resection
No role for chemotherapy or radiation for pure mature teratoma recurrence

Autologous HSCT is used in disorders that do not primarily involve haemopoietic stem cells, including testicular germ cell tumours ^[20]. High-dose chemotherapy with autologous stem cell rescue may be considered for:

Relapsed / refractory immature teratoma or mixed GCTs
Not applicable to pure mature teratoma

Subtype	Surgery	Chemotherapy	Radiotherapy	Prognosis
Mature teratoma	GTR is curative	No	No	Excellent if GTR achieved (> 90% cure)
Immature teratoma	Maximal safe resection	Platinum-based	Focal ± CSI for high-grade	Good (70–80% survival)
Teratoma with malignant transformation	Maximal safe resection (critical)	Tailored to somatic malignancy	Variable	Poor — depends on resectability and malignant component
Mixed GCT with teratoma	Second-look surgery for residual teratoma	Standard NGGCT protocol	CSI	Intermediate (~60–70% survival for NGGCT overall)

High Yield Summary — Management of Intracranial Teratoma

Emergency: Obstructive hydrocephalus → EVD (gold standard for ICP monitoring) or ETV for CSF diversion ^[15]^[16]
Medical ICP management: Dexamethasone 10 mg then 4 mg Q4h for vasogenic oedema reduction ^[8]; C/I in suspected CNS lymphoma ^[8]
Maximal safe resection is the key component of treatment — confirms diagnosis, relieves ICP, establishes local control ^[1]^[2]
Mature teratoma: surgery alone is curative if GTR achieved; no chemo or RT needed
Immature teratoma: surgery + platinum-based chemotherapy ± focal radiation
Mixed GCT with teratoma: treat NGGCT components with chemo + CSI; residual teratoma → second-look surgery
CSI complications: neurocognitive impairment, ↓GH (94%), ↓ACTH (43%), ↓TSH (10%), ototoxicity, cerebrovascular disease ^[1]^[2]
Chemotherapy complications: ototoxicity (cisplatin), nephrotoxicity, myelosuppression ^[1]^[2]
Growing teratoma syndrome: residual mass enlarges after chemotherapy despite normalising markers → benign mature teratoma requiring second-look surgery
Endocrine replacement: lifelong for suprasellar teratomas causing hypopituitarism; replace cortisol BEFORE thyroxine

Active Recall - Management of Intracranial Teratoma

References

^[1] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Treatment of medulloblastoma and GCTs (pp. 532, 534) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Treatment of medulloblastoma and GCTs (pp. 1260, 1262, 1264) ^[8] Senior notes: Ryan Ho Neurology.pdf — Management of intracranial tumours (pp. 163) ^[15] Lecture slides: GC 111. Raised intracranial pressure and hydrocephalus.pdf — ICP monitoring, EVD ^[16] Lecture slides: GC 208. Unconscious after an accident Head injury.pdf — ICP monitoring slide ^[17] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf — Surgical approaches, complications ^[18] AOS material: AOS - Pathology.pdf — Frozen section indications ^[19] Senior notes: Maksim Surgery Notes.pdf — Testicular tumour management (p. 326) ^[20] Senior notes: Ryan Ho Haemtology.pdf — HSCT indications including testicular GCT (p. 153)

Complications of Intracranial Teratoma

The complications of intracranial teratoma can be organised into three broad categories:

Complications of the tumour itself (mass effect, hormonal, dissemination)
Complications of treatment (surgery, chemotherapy, radiotherapy)
Long-term sequelae (endocrine, neurocognitive, secondary malignancy)

Understanding why each complication occurs requires connecting back to the anatomy, the biology of teratomas, and the mechanisms of treatment toxicity.

12.1 Complications of the Tumour Itself

This is the most common and most immediately dangerous complication. It arises because pineal region teratomas compress the cerebral aqueduct of Sylvius, blocking CSF flow from the 3rd to the 4th ventricle. The CSF continues to be produced (~500 mL/day by the choroid plexus) but cannot drain → progressive ventricular dilatation → raised ICP.

Complication	Mechanism	Consequence
Acute hydrocephalus	Aqueductal obstruction by pineal mass	Rapid ↑ICP → headache, vomiting, drowsiness → if untreated, herniation and death
Chronic hydrocephalus	Slow-growing tumour → gradual aqueductal narrowing	Insidious cognitive decline, macrocephaly in infants (unfused sutures expand), optic atrophy from chronic papilloedema
Papilloedema → optic atrophy	Chronic raised ICP compresses both nerve and vessels ^[6] → sustained ↓axoplasmic flow + ischaemia → irreversible optic nerve damage	Permanent visual loss — no obvious vision loss initially, but will have transient BOV (blurring of vision) for head postural change ^[6]; if untreated, visual fields constrict and acuity deteriorates permanently

The ultimate consequence of uncontrolled ↑ICP. Several patterns exist depending on the location of the mass:

Herniation Type	Cause	Clinical Features
Uncal herniation	Supratentorial mass pushing medial temporal lobe (uncus) through tentorial hiatus	"Blown pupil" (fixed dilated pupil due to CN III palsy), contralateral hemiplegia (cerebral peduncle compression), reduced consciousness (reticular formation compression) ^[5]
Tonsillar herniation (coning)	Posterior fossa mass or downward transtentorial shift → cerebellar tonsils descend through foramen magnum	Cushing's triad (systemic hypertension, bradycardia, respiratory depression) ^[5] → cardiorespiratory arrest → death
Upward transtentorial herniation	Large pineal/posterior fossa mass → upward displacement through tentorial notch	Bilateral pupillary abnormalities, loss of consciousness, Cheyne-Stokes respiration
Subfalcine herniation	Early unilateral mass → cingulate gyrus displaced under falx cerebri → anterior cerebral artery compression	Bilateral lower limb weakness (ACA territory ischaemia)

Why is Herniation So Dangerous?

The brainstem contains the reticular activating system (consciousness), respiratory centres (medullary respiratory neurons), and cardiovascular centres (vasomotor control). Any compression of the brainstem is immediately life-threatening. Herniation is the final common pathway of death from intracranial mass lesions.

Complication	Mechanism	Clinical Impact
Central diabetes insipidus	Infiltration/compression of the pituitary stalk or posterior pituitary → ↓ADH (vasopressin) secretion → kidneys unable to concentrate urine	Massive polyuria (up to 10–20 L/day), severe hypernatraemia and dehydration if fluid intake is inadequate; can be life-threatening
Anterior pituitary failure (hypopituitarism)	Compression of anterior pituitary or disruption of hypothalamic-pituitary portal blood supply	GH deficiency → growth failure; ACTH deficiency → secondary adrenal insufficiency (most dangerous — can cause adrenal crisis with hypotension, hypoglycaemia, shock); TSH deficiency → central hypothyroidism; gonadotropin deficiency → delayed/absent puberty
Precocious puberty	β-hCG-secreting teratoma components (immature or mixed) mimic LH action → stimulate Leydig cells in boys → testosterone production	Early secondary sexual characteristics in boys; girls less commonly affected (β-hCG does not reliably stimulate ovarian steroidogenesis)

A unique complication of intracranial teratoma (particularly dermoid cysts and teratomas containing lipid-rich material):

Mechanism: rupture of the tumour capsule releases lipid material, keratin, and sebaceous contents into the subarachnoid space
Consequence: severe chemical (aseptic) meningitis — intense inflammatory reaction to lipid droplets on meningeal surfaces
Presentation: sudden headache, meningism, fever, altered consciousness — can mimic bacterial meningitis or SAH
Imaging clue: fat droplets visible in the subarachnoid space (bright on T1-weighted MRI, hypodense on CT)
Management: emergency surgery to remove residual tumour and irrigate the subarachnoid space; anti-inflammatory agents (corticosteroids)

Detail	Explanation
Which subtypes?	Immature teratoma, teratoma with malignant transformation, and mixed GCTs have the highest risk. Pure mature teratoma has very low risk
Mechanism	Malignant cells from the tumour surface shed into the CSF → carried by CSF flow along the subarachnoid space → deposit on the spinal cord, cauda equina, and ventricular surfaces ("drop metastases")
Consequence	Radiculopathy, myelopathy, cranial neuropathies, communicating hydrocephalus (tumour cells blocking arachnoid villi)
Detection	MRI spine with gadolinium (enhancing nodules); CSF cytology (malignant cells)

Note: extracranial metastasis is rare in primary brain tumours because there is no lymphatic drainage from the brain ^[3]^[8]. TNM staging is therefore not useful. However, leptomeningeal spread within the CNS is well-recognised.

This was discussed in the management section but deserves emphasis as a complication:

After chemotherapy for mixed GCT, the chemo-sensitive malignant components regress but the chemo-resistant mature teratoma continues to enlarge
On imaging: paradoxical growth of residual mass despite normalising tumour markers
If unrecognised: the enlarging mass can cause recurrent obstructive hydrocephalus, new focal deficits, or herniation
Management: second-look surgery for resection of the residual mature teratoma

Complications of teratoma include torsion, rupture, and malignant change (about 2% for ovarian, and variable for intracranial) ^[21]:

A mature intracranial teratoma — though histologically benign — can undergo malignant transformation of a somatic component (e.g., squamous cell carcinoma, adenocarcinoma, rhabdomyosarcoma arising within teratomatous tissue)
Teratoma with malignant transformation, e.g., SCC ^[21] — this is the specific terminology
This is a late complication, more common in larger tumours and those with prolonged follow-up
Prognosis is poor because the resulting somatic malignancy is often chemo-resistant

12.2 Complications of Treatment

Complication	Mechanism	Details
Postoperative haemorrhage	Bleeding from tumour bed, bridging veins, or vascular structures (e.g., vein of Galen, internal cerebral veins near pineal region)	May require emergency re-exploration; haemostasis is challenging in the deep pineal region
CSF rhinorrhoea (transsphenoidal approach)	Disruption of dural barrier → CSF leaks through the sphenoid sinus into the nose	Will require antibiotics to prevent ascending meningitis, as well as decision to go back to OT for repair ^[17]
Meningitis	Ascending infection through CSF leak, wound infection, or contamination during surgery	Monitor for fever, headache, neck stiffness, photophobia; treat with IV antibiotics penetrating the BBB
Iatrogenic hypopituitarism / diabetes insipidus ^[17]	Surgical damage to the pituitary stalk, hypothalamus, or posterior pituitary during suprasellar tumour resection	Often permanent; requires lifelong hormone replacement
Posterior fossa syndrome (cerebellar mutism) ^[1]^[2]	Postoperative complication caused by injury to cerebellar vermis or dentate nuclei during resection of tumours in midline cerebellum. Appears 1–2 days after surgery and resolves within weeks to months. Characterised by impaired language production with emotional lability ^[1]^[2]	More common after medulloblastoma resection but can occur with any posterior fossa approach for pineal tumours
Visual deterioration	Damage to optic nerves, chiasm, or visual cortex during surgical approach	Risk is particularly high with suprasellar teratomas where the tumour is intimately related to the optic apparatus
Seizures	Cortical irritation from surgical manipulation of cerebral hemisphere	Postoperative anticonvulsant prophylaxis if cortical manipulation was involved
Residual tumour / recurrence ^[17]	Incomplete resection due to tumour adherence to critical structures (deep veins, brainstem)	Especially for large tumours ^[17]; surveillance MRI is essential; may require re-operation
EVD-related complications	Infection (ventriculitis), catheter malposition, over-drainage, haemorrhage along tract	Risk of infection, iatrogenic trauma ^[15]

Complication	Causative Agent	Mechanism	Management
Ototoxicity ^[1]^[2]	Cisplatin	Cisplatin accumulates in the outer hair cells of the cochlea and generates reactive oxygen species → irreversible damage to hair cells → sensorineural hearing loss (high-frequency first, then progressive)	Serial audiometry monitoring; dose reduction or switch to carboplatin if severe; hearing aids if permanent
Nephrotoxicity	Cisplatin	Direct tubular damage → acute kidney injury, electrolyte wasting (Mg²⁺, K⁺), chronic renal impairment	Aggressive IV hydration before/during/after cisplatin; monitor RFT and electrolytes
Myelosuppression	Cisplatin, etoposide, cyclophosphamide, ifosfamide	Cytotoxic effect on rapidly dividing bone marrow precursors → pancytopenia (nadir ~10–14 days)	Neutropenic sepsis risk → monitor CBC, febrile neutropenia protocols, G-CSF support
Peripheral neuropathy	Cisplatin, vincristine	Axonal damage to peripheral nerves → sensory > motor neuropathy (glove-and-stocking distribution)	Dose reduction; irreversible in severe cases
Gonadal toxicity	Alkylating agents (cyclophosphamide, ifosfamide)	Damage to spermatogonia and oocytes → oligospermia/azoospermia, premature ovarian failure	Fertility preservation before treatment: cryopreservation of sperm ^[19]; oocyte/embryo cryopreservation in females if feasible
Haemorrhagic cystitis	Ifosfamide, cyclophosphamide	Metabolite acrolein is excreted in urine → direct toxic damage to bladder urothelium	Mesna (2-mercaptoethanesulfonate) co-administration; adequate hydration
Secondary malignancy	Alkylating agents, etoposide	DNA damage to normal cells → ↑risk of treatment-related MDS/AML (typically 2–7 years post-treatment, especially with etoposide → 11q23 rearrangements)	Long-term surveillance with CBC
Nausea / vomiting	Most agents	Stimulation of chemoreceptor trigger zone and vagal afferents	Prophylactic anti-emetics (5-HT3 antagonists e.g., ondansetron; NK1 antagonists e.g., aprepitant; dexamethasone)

Radiotherapy complications ^[1]^[2]:

Complication	Timing	Mechanism	Details
Ototoxicity ^[1]^[2]	Subacute to late	Radiation damage to cochlear structures; synergistic with cisplatin ototoxicity	Additive hearing loss when combined with cisplatin
Short stature (↓GH) ^[1]^[2]	Late	Radiation to the hypothalamic-pituitary axis → GH deficiency (most sensitive pituitary axis to radiation); also direct spinal radiation → vertebral growth plate damage	↓GH seen in 94% of children after CSI ^[1]^[2]
Endocrine abnormalities ^[1]^[2]	Late	Progressive radiation-induced hypopituitarism; order of sensitivity: GH > gonadotropins > ACTH > TSH	↓GH (94%), ↓ACTH (43%), ↓TSH (10%) ^[1]^[2]
Cerebrovascular abnormalities (stroke, intracranial haemorrhage) ^[1]^[2]	Late (years to decades)	Radiation-induced vasculopathy → accelerated atherosclerosis, vessel wall fibrosis, moyamoya-like vasculopathy	Surveillance with vascular imaging if new neurological symptoms
Neurocognitive impairment	Late	Craniospinal radiation is avoided or delayed in children due to severe toxicity to the rapidly developing CNS such as neurocognitive impairment ^[1]^[2] — radiation damages oligodendrocytes and neural stem cells → demyelination, white matter volume loss, impaired neurogenesis	↓IQ (20–30 points in young children); learning difficulties; memory impairment; more severe in younger children (< 5 years)
Radiation-associated secondary malignancy ^[22]	Very late (10–30 years)	Radiation-induced DNA mutations in normal tissue → new primary tumour (meningioma, glioma, thyroid cancer, sarcoma)	Lifetime risk approximately 1 in 1000 ^[22]; surveillance for new lesions on follow-up imaging
Radiation necrosis	Months to years	Focal necrosis of irradiated brain tissue due to vascular endothelial damage → local ischaemia → necrosis	Can mimic tumour recurrence on imaging ("pseudoprogression"); differentiated by MR perfusion/spectroscopy or PET; may require surgical excision or bevacizumab
Leukoencephalopathy	Late	Diffuse white matter injury from cranial irradiation	Progressive cognitive decline, gait disturbance; seen on MRI as periventricular T2/FLAIR hyperintensity

High Yield AOS Point — Secondary Malignancy After Radiotherapy

Radiation-associated 2nd malignancy may occur anywhere after a prior course of radical radiotherapy and the lifetime risk of having it is about 1 in 1000 ^[22].

Key exam nuance: Dwarfism (short stature) may occur after radical radiotherapy to a child but will NOT happen in an adult who is fully grown up. Hypopituitarism may occur after radiotherapy to the skull base or brain but does NOT happen if the site of previous radiotherapy is outside this area. Neurocognitive dysfunction will NOT happen if the site of previous radiation is outside the brain ^[22]. The only universally applicable long-term RT complication is secondary malignancy.

These are complications that may only manifest years to decades after treatment, particularly relevant because intracranial teratomas predominantly affect children and adolescents who will live for many decades post-cure.

Sequelae	Mechanism	Monitoring
Endocrine dysfunction (lifelong)	From tumour itself (suprasellar) + surgical damage + radiation-induced hypopituitarism	Annual endocrine assessment; lifelong hormone replacement as needed
Growth failure	GH deficiency (tumour, surgery, or radiation) + vertebral growth plate damage from spinal radiation	Height monitoring, bone age assessment, GH replacement after adequate tumour-free interval
Infertility	Gonadotropin deficiency (central) + direct gonadal toxicity from chemotherapy (especially alkylating agents)	Fertility counselling pre-treatment; cryopreservation; assisted reproductive technologies when appropriate
Neurocognitive impairment	White matter damage from radiation; hydrocephalus-related damage; surgical damage	Neuropsychological testing; educational support; cognitive rehabilitation
Epilepsy	Cortical gliosis from surgical manipulation or tumour-related cortical damage	Anticonvulsant therapy; monitoring; driving restrictions
Psychosocial impact	Chronic illness in formative years, body image issues (surgical scars, growth failure), cognitive difficulties	Psychological support, peer support groups, social work involvement
Obesity and metabolic syndrome	Hypothalamic damage (from tumour or treatment) → loss of satiety regulation → hyperphagia; GH deficiency → ↑visceral fat; reduced physical activity from neurological sequelae	Dietary counselling, exercise, metabolic screening
Visual impairment	Optic nerve/chiasm damage from tumour or surgery; chronic papilloedema → optic atrophy	Ophthalmological follow-up; visual rehabilitation
Hearing loss	Cisplatin + radiation ototoxicity (synergistic)	Serial audiometry; hearing aids; cochlear implant in severe cases

Subtype	Tumour-Related Complications	Treatment-Related Complications	Recurrence Risk
Mature teratoma	Hydrocephalus, Parinaud, endocrine dysfunction (if suprasellar), chemical meningitis (rupture), malignant transformation (~2%)	Surgical morbidity only (no chemo/RT toxicity)	Low if GTR; moderate if STR (local recurrence)
Immature teratoma	Same as above + higher risk of leptomeningeal dissemination	Surgical + chemotherapy toxicity (ototoxicity, nephrotoxicity, myelosuppression) ± radiation toxicity	Moderate; depends on grade and extent of resection
Teratoma with malignant transformation	Same + aggressive local invasion by the malignant component	Full multimodal toxicity	High — depends on the somatic malignancy type
Mixed GCT with teratoma	Same + growing teratoma syndrome after chemotherapy	Full multimodal toxicity (chemo + CSI)	Variable; NGGCT components drive prognosis

High Yield Summary — Complications of Intracranial Teratoma

Tumour complications:

Obstructive hydrocephalus → ↑ICP → herniation (most immediately life-threatening)
Brain herniation: uncal (CN III palsy + contralateral hemiplegia), tonsillar (Cushing's triad → cardiorespiratory arrest)
Endocrine failure: central DI, hypopituitarism, precocious puberty (β-hCG-driven)
Tumour rupture → chemical meningitis (lipid material in subarachnoid space)
Leptomeningeal dissemination (immature/malignant subtypes)
Malignant transformation (~2% for mature teratoma → SCC, adenocarcinoma, sarcoma)

Treatment complications: 7. Surgical: postoperative haemorrhage, CSF rhinorrhoea → ascending meningitis, iatrogenic hypopituitarism/DI, posterior fossa syndrome (cerebellar mutism), residual/recurrence ^[1]^[2]^[17] 8. Chemotherapy: ototoxicity (cisplatin), nephrotoxicity, myelosuppression, gonadal toxicity, secondary MDS/AML ^[1]^[2] 9. Radiotherapy: ↓GH (94%), ↓ACTH (43%), ↓TSH (10%), neurocognitive impairment, cerebrovascular disease, secondary malignancy (lifetime risk ~1 in 1000) ^[1]^[2]^[22]

Long-term sequelae: 10. Endocrine dysfunction (lifelong replacement), growth failure, infertility, neurocognitive impairment, epilepsy, psychosocial impact

Active Recall - Complications of Intracranial Teratoma

References

^[1] Senior notes: MBBS Final MB (Pediatrics) (Felix PY Lai).pdf — Treatment and complications of medulloblastoma/GCTs (pp. 532, 534) ^[2] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf — Treatment and complications of medulloblastoma/GCTs (pp. 1262, 1264) ^[3] Senior notes: Adrian Lui Pediatrics Notes.pdf — Section 11.1.3 Brain Tumors (pp. 429, 432) ^[5] Senior notes: Maksim Medicine Notes.pdf — Increased ICP, herniation syndromes (p. 278) ^[6] AOS material: AOS - Ophthalmology (Ans:Notes).pdf — Neuro-ophthalmology case (papilloedema, raised ICP) ^[8] Senior notes: Ryan Ho Neurology.pdf — Pineal tumours, brain tumour management and complications (pp. 163, 167) ^[15] Lecture slides: GC 111. Raised intracranial pressure and hydrocephalus.pdf — EVD, ICP monitoring ^[17] Senior notes: Block A - I keep on bumping into people on my side_ pituitary tumours; hypopituitarism.pdf — Surgical complications ^[19] Senior notes: Maksim Surgery Notes.pdf — Testicular GCT management, fertility preservation (p. 326) ^[21] Lecture slides: Cancer Block - Cervical Cancer Pathology - Pathology of Tumours of the Ovary and Fallopian Tube.pdf — Teratoma complications ^[22] AOS material: AOS - Cancer Medicine.pdf — Radiation-associated secondary malignancy MCQ (p. 32)

High Yield Summary

Intracranial teratoma = a non-germinomatous GCT (NGGCT) composed of tissues from all three germ layers, arising in midline structures (pineal > suprasellar)
Epidemiology: peak 10–12 years, 6× more common in Asians vs Caucasians, male predominance for pineal, female for suprasellar. 3rd most common paediatric brain tumour in HK
Pathogenesis: aberrant primordial germ cell migration → ectopic totipotent cells in midline → differentiation into multi-lineage tissues
Classification: Mature (marker −, benign-behaving, chemo-resistant) vs Immature (AFP/β-hCG +/−, more aggressive) vs Malignant transformation
Pineal presentation = obstructive hydrocephalus (↑ICP) + Parinaud syndrome (50%) (upgaze palsy, light-near dissociation, convergence-retraction nystagmus)
Suprasellar presentation = endocrine dysfunction (DI, hypopituitarism, precocious/delayed puberty) + visual field defects (bitemporal hemianopia)
Imaging: CT shows pathognomonic heterogeneous mass with fat + calcification + soft tissue
Tumour markers: Mature teratoma = AFP −, β-hCG −; Immature teratoma = AFP +/−, β-hCG +/−; always check both serum AND CSF (CSF is more sensitive)
CN VI palsy is a false localising sign of raised ICP — long intracranial course makes it vulnerable to stretch injury
Cushing's triad (hypertension, bradycardia, respiratory depression) is a late ominous sign of brainstem herniation

High Yield Summary — Differential Diagnosis of Intracranial Teratoma

The core DDx for a marker-negative midline intracranial mass in a child: pure germinoma, mature teratoma, craniopharyngioma, pineocytoma, glioma, ependymoma, LCH — biopsy is mandatory
If markers are positive (AFP or β-hCG), the differential narrows to NGGCTs (yolk sac tumour, choriocarcinoma, immature teratoma, mixed GCT) — biopsy may not be needed
Imaging is the key discriminator: teratoma = heterogeneous with fat + calcification; germinoma = homogeneous, intensely enhancing; craniopharyngioma = cystic with eggshell calcification
In HK, intracranial GCTs are 6× more common than in Caucasians → always high on the DDx for midline paediatric brain mass
Pineal region DDx: germinoma > teratoma > pineoblastoma > glioma
Suprasellar region DDx: craniopharyngioma > germinoma > teratoma > optic pathway glioma > pituitary adenoma > LCH > Rathke's cleft cyst

High Yield Summary — Diagnosis of Intracranial Teratoma

Three-pillar approach: Clinical presentation → tumour markers (serum + CSF) → histopathology
If markers elevated (AFP and/or β-hCG): can diagnose NGGCT subtype without biopsy; elevated AFP rules out pure germinoma ^[1]^[2]
If markers negative: biopsy is mandatory — must differentiate mature teratoma from pure germinoma, craniopharyngioma, PNET, ependymoma, LCH ^[1]^[2]
CT findings: heterogeneous midline mass with fat (hypodense) + calcification (hyperdense) — virtually pathognomonic
MRI findings: mixed T1/T2 signal; fat confirmed by fat-suppression sequences; heterogeneous enhancement
Histopathology is the gold standard — "histological examination of biopsy specimen remains the most important component of diagnostic evaluation of brain tumours" ^[1]^[2]
CSF markers are more sensitive than serum markers — always measure both ^[1]^[2]^[3]
INI1 IHC is critical to exclude AT/RT in young children — retained in teratoma, lost in AT/RT
For suprasellar teratomas: complete endocrine work-up including both anterior and posterior pituitary hormones ^[14]
Staging: MRI spine + CSF cytology — TNM staging is not useful for intracranial tumours

High Yield Summary — Management of Intracranial Teratoma

Emergency: Obstructive hydrocephalus → EVD (gold standard for ICP monitoring) or ETV for CSF diversion ^[15]^[16]
Medical ICP management: Dexamethasone 10 mg then 4 mg Q4h for vasogenic oedema reduction ^[8]; C/I in suspected CNS lymphoma ^[8]
Maximal safe resection is the key component of treatment — confirms diagnosis, relieves ICP, establishes local control ^[1]^[2]
Mature teratoma: surgery alone is curative if GTR achieved; no chemo or RT needed
Immature teratoma: surgery + platinum-based chemotherapy ± focal radiation
Mixed GCT with teratoma: treat NGGCT components with chemo + CSI; residual teratoma → second-look surgery
CSI complications: neurocognitive impairment, ↓GH (94%), ↓ACTH (43%), ↓TSH (10%), ototoxicity, cerebrovascular disease ^[1]^[2]
Chemotherapy complications: ototoxicity (cisplatin), nephrotoxicity, myelosuppression ^[1]^[2]
Growing teratoma syndrome: residual mass enlarges after chemotherapy despite normalising markers → benign mature teratoma requiring second-look surgery
Endocrine replacement: lifelong for suprasellar teratomas causing hypopituitarism; replace cortisol BEFORE thyroxine

High Yield Summary — Complications of Intracranial Teratoma

Tumour complications:

Obstructive hydrocephalus → ↑ICP → herniation (most immediately life-threatening)
Brain herniation: uncal (CN III palsy + contralateral hemiplegia), tonsillar (Cushing's triad → cardiorespiratory arrest)
Endocrine failure: central DI, hypopituitarism, precocious puberty (β-hCG-driven)
Tumour rupture → chemical meningitis (lipid material in subarachnoid space)
Leptomeningeal dissemination (immature/malignant subtypes)
Malignant transformation (~2% for mature teratoma → SCC, adenocarcinoma, sarcoma)

Long-term sequelae: 10. Endocrine dysfunction (lifelong replacement), growth failure, infertility, neurocognitive impairment, epilepsy, psychosocial impact

Intracranial Teratoma

1. Definition

2. Epidemiology

2.1 General Epidemiology of Intracranial GCTs (Including Teratoma)

2.2 Teratoma-Specific Epidemiology

2.3 Risk Factors

3. Anatomy and Function of Relevant Structures

3.1 Pineal Region

3.2 Suprasellar Region

3.3 Other Sites

4. Aetiology and Pathophysiology

4.1 Origin of Intracranial Teratomas — The Germ Cell Migration Theory

4.2 Molecular Pathogenesis

4.3 Histopathology of Teratomas

4.4 Tumour Markers

5. Classification

5.1 WHO Classification of CNS Tumours (5th Edition, 2021) — Germ Cell Tumours

5.2 Classification of Intracranial Teratoma by Location

5.3 Classification by Age of Presentation

6. Clinical Features

6.1 Symptoms

A. Symptoms of Raised Intracranial Pressure (↑ICP)

B. Symptoms from Local Mass Effect — Pineal Region

C. Symptoms from Local Mass Effect — Suprasellar Region

D. Other Symptoms

6.2 Signs

A. Signs of Raised ICP

B. Parinaud Syndrome (Dorsal Midbrain Syndrome) — Pineal Region Teratoma

C. Signs of Endocrine Dysfunction (Suprasellar Teratoma)

D. Signs on Imaging (Preview — Described in Detail in Diagnostic Section)

7. Special Considerations for Hong Kong

8. Summary of Pathophysiology → Clinical Feature Connections

Active Recall - Intracranial Teratoma (Definition to Clinical Features)

References

9.1 Approach to the Differential

9.2 Differential Diagnosis by Location

A. Pineal Region Mass

B. Suprasellar Region Mass

C. Other Locations / General DDx of Paediatric Brain Tumours

9.3 Key Discriminating Features on Imaging

9.4 Key Discriminating Features by Tumour Markers

9.5 Differential Diagnosis of ↑ICP Presentation

9.6 Differential Diagnosis Decision Algorithm

9.7 DDx Unique to Neonatal/Congenital Intracranial Teratoma

Active Recall - DDx of Intracranial Teratoma

10.1 Diagnostic Criteria — First Principles

10.2 Diagnostic Criteria by Teratoma Subtype

10.3 Diagnostic Algorithm

10.4 Investigation Modalities — Detailed Breakdown

A. Neuroimaging

i. CT Brain (Non-contrast then Contrast)

ii. MRI Brain with Gadolinium Contrast

iii. Advanced Neuroimaging (Pre-operative Planning)

iv. MRI Spine (Staging)

B. Tumour Markers

C. Lumbar Puncture and CSF Analysis

D. Histopathological Diagnosis — The Gold Standard

Methods of obtaining tissue:

Histopathological features by teratoma subtype:

Immunohistochemistry (IHC) panel:

E. Endocrine Investigations

F. Ophthalmological Assessment

G. Blood Tests — Baseline and Pre-treatment

10.5 Staging Investigations

10.6 Summary Table — Complete Investigation Approach

Active Recall - Diagnosis and Investigations for Intracranial Teratoma

11.1 Principles of Management — First Principles

11.2 Management Algorithm — Overview

11.3 Emergency Management of Raised ICP

A. Medical Management of Raised ICP

B. Surgical CSF Diversion for Hydrocephalus

11.4 Definitive Surgery — Maximal Safe Resection

A. Surgical Approaches

B. Operative Techniques

C. Goals of Surgery by Teratoma Subtype

D. Post-operative Complications

11.5 Adjuvant Therapy

A. Chemotherapy

B. Radiotherapy

C. "Second-Look" Surgery and Growing Teratoma Syndrome